US20030232863A1 - Cathepsin cysteine protease inhibitors - Google Patents

Cathepsin cysteine protease inhibitors Download PDF

Info

Publication number
US20030232863A1
US20030232863A1 US10/377,377 US37737703A US2003232863A1 US 20030232863 A1 US20030232863 A1 US 20030232863A1 US 37737703 A US37737703 A US 37737703A US 2003232863 A1 US2003232863 A1 US 2003232863A1
Authority
US
United States
Prior art keywords
leucinamide
trifluoro
ethyl
cyanomethyl
biphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/377,377
Other languages
English (en)
Inventor
Christopher Bayly
Cameron Black
Serge Leger
Chun Li
Dan McKay
Christophe Mellon
Jacques Gauthier
Vouy-Linh Truong
Cheuk Lau
Michel Therien
Michael Green
Bernard Hirschbein
James Janc
James Palmer
Chitra Baskaran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27807943&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20030232863(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to US10/377,377 priority Critical patent/US20030232863A1/en
Publication of US20030232863A1 publication Critical patent/US20030232863A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/17—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and doubly-bound oxygen atoms bound to the same acyclic carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • C07C255/25—Aminoacetonitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • C07C255/29—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton containing cyano groups and acylated amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Definitions

  • disorders in humans and other mammals involve or are associated with abnormal bone resorption.
  • Such disorders include, but are not limited to, osteoporosis, glucocorticoid induced osteoporosis, Paget's disease, abnormally increased bone turnover, periodontal disease, tooth loss, bone fractures, rheumatoid arthritis, osteoarthritis, periprosthetic osteolysis, osteogenesis imperfecta, metastatic bone disease, hypercalcemia of malignancy, and multiple myeloma.
  • osteoporosis which in its most frequent manifestation occurs in postmenopausal women.
  • Osteoporosis is a systemic skeletal disease characterized by a low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture. Osteoporotic fractures are a major cause of morbidity and mortality in the elderly population. As many as 50% of women and a third of men will experience an osteoporotic fracture. A large segment of the older population already has low bone density and a high risk of fractures. There is a significant need to both prevent and treat osteoporosis and other conditions associated with bone resorption. Because osteoporosis, as well as other disorders associated with bone loss, are generally chronic conditions, it is believed that appropriate therapy will typically require chronic treatment.
  • Osteoporosis is characterized by progressive loss of bone architecture and mineralization leading to the loss in bone strength and an increased fracture rate.
  • the skeleton is constantly being remodeled by a balance between osteoblasts that lay down new bone and osteoclasts that breakdown, or resorb, bone.
  • the balance between bone formation and resorption is disrupted; bone is removed at a faster rate.
  • Such a prolonged imbalance of resorption over formation leads to weaker bone structure and a higher risk of fractures.
  • Bone resorption is primarily performed by osteoclasts, which are multinuclear giant cells. Osteoclasts resorb bone by forming an initial cellular attachment to bone tissue, followed by the formation of an extracellular compartment or lacunae.
  • the lacunae are maintained at a low pH by a proton-ATP pump.
  • the acidified environment in the lacunae allows for initial demineralization of bone followed by the degradation of bone proteins or collagen by proteases such as cysteine proteases. See Delaisse, J. M. et al., 1980 , Biochem J 192:365-368; Delaisse, J. et al., 1984 , Biochem Biophys Res Commun: 441-447; Delaisse, J.
  • Collagen constitutes 95% of the organic matrix of bone. Therefore, proteases involved in collagen degradation are an essential component of bone turnover, and as a consequence, the development and progression of osteoporosis.
  • Cathepsins belong to the papain superfamily of cysteine proteases. These proteases function in the normal physiological as well as pathological degradation of connective tissue. Cathepsins play a major role in intracellular protein degradation and turnover and remodeling. To date, a number of cathepsin have been identified and sequenced from a number of sources. These cathepsins are naturally found in a wide variety of tissues. For example, cathepsin B, F, H, L, K, S, W, and Z have been cloned. Cathepsin K (which is also known by the abbreviation cat K) is also known as cathepsin O and cathepsin O2.
  • Cathepsin L is implicated in normal lysosomal proteolysis as well as several diseases states, including, but not limited to, metastasis of melanomas.
  • Cathepsin S is implicated in Alzheimer's disease and certain autoimmune disorders, including, but not limited to juvenile onset diabetes, multiple sclerosis, pemphigus vulgaris, Graves' disease, myasthenia gravis, systemic lupus erythemotasus, rheumatoid arthritis and Hashimoto's thyroiditis; allergic disorders, including, but not limited to asthma; and allogenic immunbe responses, including, but not limited to, rejection of organ transplants or tissue grafts. Increased Cathepsin B levels and redistribution of the enzyme are found in tumors, suggesting a role in tumor invasion and matastasis.
  • Cathpsin B activity is implicated in such disease states as rheumatoid arthritis, osteoarthritis, pneumocystisis carinii, acute pancreatitis, inflammatory airway disease and bone and joint disorders.
  • Cysteine protease inhibitors such as E-64 (trans-epoxysuccinyl-L-leucylamide-(4-guanidino)butane) are known to be effective in inhibiting bone resorption. See Delaisse, J. M. et al., 1987 , Bone 8:305-313, which is hereby incorporated by reference in its entirety. Recently, cathepsin K was cloned and found specifically expressed in osteoclasts See Tezuka, K. et al., 1994 , J Biol Chem 269:1106-1109; Shi, G. P. et al.,1995 , FEBS Lett 357:129-134; Bromme, D.
  • Cathepsin K is synthesized as a 37 kDa pre-pro enzyme, which is localized to the lysosomal compartment and where it is presumably autoactivated to the mature 27 kDa enzyme at low pH. See McQueney, M. S. et al., 1997 , J Biol Chem 272:13955-13960; Littlewood-Evans, A. et al., 1997 , Bone 20:81-86, which are hereby incorporated by reference in their entirety. Cathepsin K is most closely related to cathepsin S having 56% sequence identity at the amino acid level.
  • the S 2 P 2 substrate specificity of cathepsin K is similar to that of cathepsin S with a preference in the P1 and P2 positions for a positively charged residue such as arginine, and a hydrophobic residue such as phenylalanine or leucine, respectively. See Bromme, D. et al., 1996 , J Biol Chem 271: 2126-2132; Bossard, M. J. et al., 1996 , J Biol Chem 271:12517-12524, which are hereby incorporated by reference in their entirety.
  • Cathepsin K is active at a broad pH range with significant activity between pH 4-8, thus allowing for good catalytic activity in the resorption lacunae of osteoclasts where the pH is about 4-5.
  • the present invention relates to compounds that are capable of treating and/or preventing cathepsin dependent conditions or disease states in a mammal in need thereof.
  • One embodiment of the present invention is illustrated by a compound of Formula I, and the pharmaceutically acceptable salts, stereoisomers and N-oxide derivatives thereof:
  • the present invention relates to compounds of the following chemical formula:
  • R 1 is hydrogen, C 1-6 alkyl or C 2-6 alkenyl wherein said alkyl and alkenyl groups are optionally substituted with one to six halo, C 3-6 cycloalkyl, —SR 9 , —SR 12 , —SOR 9 , —SOR 12 , —SO 2 R 9 , —SO 2 R 12 , —SO 2 CH(R 12 )(R 11 ), —OR 12 , —OR 9 , —N(R 12 ) 2 , aryl, heteroaryl or heterocyclyl wherein said aryl, heteroaryl and heterocyclyl groups are optionally substituted with one or two substitutents independently selected from C 1-6 alkyl, halo, hydroxyalkyl, hydroxy, alkoxy or keto;
  • R 2 is hydrogen, C 1-6 alkyl or C 2-6 alkenyl wherein said alkyl and alkenyl groups are optionally substituted with one to six halo, C 3-6 cycloalkyl, —SR 9 , —SR 12 , —SOR 9 , —SOR 12 , —SO 2 R 9 , —SO 2 R 12 , —SO 2 CH(R 12 )(R 11 ), —OR 12 , —OR 9 , —N(R 12 ) 2 , aryl, heteroaryl or heterocyclyl wherein said aryl, heteroaryl and heterocyclyl groups are optionally substituted with one or two substitutents independently selected from C 1-6 alkyl, halo, hydroxyalkyl, hydroxy, alkoxy or keto;
  • R 1 and R 2 can be taken together with the carbon atom to which they are attached to form a C 3-8 cycloalkyl or heterocyclyl ring wherein said ring system is optionally substituted with one or two substituents independently selected from C 1-6 alkyl, hydroxyalkyl, haloalkyl, or halo;
  • R 3 is hydrogen, C 1-6 alkyl or C 2-6 alkenyl wherein said alkyl and alkenyl groups are optionally substituted with C 3-6 cycloalkyl or one to six halo;
  • R 4 is hydrogen, C 1-6 alkyl or C 2-6 alkenyl wherein said alkyl and alkenyl groups are optionally substituted with C 3-6 cycloalkyl or one to six halo; or R 3 and R 4 can be taken together with the carbon atom to which they are attached to form a C 3-8 cycloalkyl ring, C 5-8 cycloalkenyl ring, or five to seven membered heterocyclyl wherein said cycloalkyl, cycloalkenyl and heterocyclyl groups are optionally substituted with one or two substitutents independently selected from C 1-6 alkyl, halo, hydroxyalkyl, hydroxy, alkoxy or keto;
  • R 5 is selected from hydrogen or C 1-6 alkyl substituted with 1-6 halo
  • R 6 is aryl, heteroaryl, C 1-6 haloalkyl, arylalkyl or heteroarylalkyl, wherein said aryl, heteroaryl, arylalkyl and heteroarylalkyl groups are optionally substituted with one, two, or three substituents independently selected from halo, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, haloalkoxy, —SR 9 , —SR 12 , —SOR 9 , —SOR 12 , —SO 2 R 9 , —SO 2 R 12 , —SO 2 CH(R 12 )(R 11 ), —OR 12 , —N(R 10 )(R 11 ), cyano, or aryl which is optionally substituted with —SO 2 R 12 ;
  • each D is independently C 1-3 alkyl, C 2-3 alkenyl, C 2-3 alkynyl, aryl, heteroaryl, C 3-8 cycloalkyl or heterocyclyl wherein each said aryl, heteroaryl, cycloalkyl and heterocyclyl groups, which may be monocyclic or bicyclic, is optionally substituted on either the carbon or the heteroatom with one to five substituents independently selected from C 1-6 alkyl, haloalkyl, halo, keto, alkoxy, —SR 9 , —SR 12 , —OR 9 , —OR 12 , N(R 12 ) 2 , —SO 2 R 9 , or —SO 2 R 10 ;
  • R 7 is hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkyloxy, halo, nitro, cyano, aryl, heteroaryl, C 3-8 cycloalkyl, heterocyclyl, —C(O)OR 10 , —C(O)OSi[CH(CH 3 ) 2 ] 3 , —OR 9 , —OR 10 , —C(O)R 10 , —R 10 C(O)R 9 , —C(O)R 9 , —C(O)N(R a )(R b ), —C(O)N(R 12 )(R 12 ), —C(O)N(R 10 )(R 11 ), —C(R 10 )(R 11 )OH, —SR 12 , —SR 9 , —R 10 SR 9 , —R 9 , —C(R 9 ) 3
  • R 8 is hydrogen or C 1-6 alkyl
  • R 4 and R 8 can be taken together with any of the atoms to which they may be attached or are between them to form a 4-10 membered heterocyclyl ring system wherein said ring system, which may be monocyclic or bicyclic, is optionally substituted with one or two substituents independently selected from C 1-6 alkyl, halo, hydroxyalkyl, hydroxy, keto, —OR 10 , —SR 10 or —N(R 10 ) 2 ;
  • R 9 is selected from the group consisting of hydrogen, aryl, aryl(C 1-4 ) alkyl, heteroaryl, heteroaryl(C 1-4 )alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl(C 1-4 )alkyl, and heterocyclyl(C 1-4 )alkyl wherein said groups can be optionally substituted with one, two, or three substituents independently selected from halo, alkoxy or —SO 2 R 12 ;
  • R 10 is hydrogen or C 1-6 alkyl
  • R 11 is hydrogen or C 1-6 alkyl
  • R 12 is hydrogen or C 1-6 alkyl which is optionally substituted with one, two, or three substituents independently selected from halo, alkoxy, cyano, —NR 10 or —SR 10 ;
  • R a is hydrogen, C 1-6 alkyl, (C 1-6 alkyl)aryl, (C 1-6 alkyl)hydroxyl, —O(C 1-6 alkyl), hydroxyl, halo, aryl, heteroaryl, C 3-8 cycloalkyl, heterocyclyl, wherein said alkyl, aryl, heteroaryl, C 3-8 cycloalkyl and heterocyclyl can be optionally substituted on either the carbon or the heteroatom with one, two, or three substituents independently selected from C 1-6 alkyl or halo;
  • R b is hydrogen, C 1-6 alkyl, (C 1-6 alkyl)aryl, (C 1-6 alkyl)hydroxyl, alkoxyl, hydroxyl, halo, aryl, heteroaryl, C 3-8 cycloalkyl, heterocyclyl,wherein said alkyl, aryl, heteroaryl, C 3-8 cycloalkyl and heterocyclyl can be optionally substituted on either the carbon or the heteroatom with one, two, or three substituents independently selected from C 1-6 alkyl or halo;
  • R a and R b can be taken together with the carbon atom to which they are attached or are between them to form a C 3-8 cycloalkyl ring or C 3-8 heterocyclyl ring wherein said 3-8 membered ring system may be optionally substituted with one or two substituents independently selected from C 1-6 alkyl and halo;
  • R c is hydrogen or C 1-6 alkyl which is optionally substituted with one, two, or three substituents independently selected from halo or —OR 9 ;
  • R d is hydrogen or C 1-6 alkyl which is optionally substituted with one, two, or three substituents independently selected from halo or —OR 9 ;
  • R c and R d can be taken together with the nitrogen atom to which they are attached or are between them to form a C 3-8 heterocyclyl ring which is optionally substituted with one or two substituents independently selected from C 1-6 alkyl, halo hydroxyalkyl, hydroxy, alkoxy or keto;
  • n is independently selected from an integer from zero to three;
  • each m is independently selected from an integer from zero to two;
  • the present invention relates to compounds of the following chemical formula:
  • R 1 is hydrogen, C 1-6 alkyl or C 2-6 alkenyl wherein said alkyl and alkenyl groups are optionally substituted with one to six halo, C 3-6 cycloalkyl, —SR 9 , —SR 12 , —SOR 9 , —SOR 12 , —SO 2 R 9 , —SO 2 R 12 , —SO 2 CH(R 12 )(R 11 ), —OR 12 , —OR 9 , —N(R 12 ) 2 , aryl, heteroaryl or heterocyclyl wherein said aryl, heteroaryl and heterocyclyl groups are optionally substituted with one or two substitutents independently selected from C 1-6 alkyl, halo, hydroxyalkyl, hydroxy, alkoxy or keto;
  • R 2 is hydrogen, C 1-6 alkyl or C 2-6 alkenyl wherein said alkyl and alkenyl groups are optionally substituted with one to six halo, C 3-6 cycloalkyl, —SR 9 , —SR 12 , —SOR 9 , —SOR 12 , —SO 2 R 9 , —SO 2 R 12 , —SO 2 CH(R 12 )(R 11 ), —OR 12 , —OR 9 , —N(R 12 ) 2 , aryl, heteroaryl or heterocyclyl wherein said aryl, heteroaryl and heterocyclyl groups are optionally substituted with one or two substitutents independently selected from C 1-6 alkyl, halo, hydroxyalkyl, hydroxy, alkoxy or keto;
  • R 1 and R 2 can be taken together with the carbon atom to which they are attached to form a C 3-8 cycloalkyl or heterocyclyl ring wherein said ring system is optionally substituted with one or two substituents independently selected from C 1-6 alkyl, hydroxyalkyl, haloalkyl, or halo;
  • R 3 is hydrogen, C 1-6 alkyl or C 2-6 alkenyl wherein said alkyl and alkenyl groups are optionally substituted with C 3-6 cycloalkyl or one to six halo;
  • R 4 is hydrogen, C 1-6 alkyl or C 2-6 alkenyl wherein said alkyl and alkenyl groups are optionally substituted with C 3-6 cycloalkyl or one to six halo;
  • R 3 and R 4 can be taken together with the carbon atom to which they are attached to form a C 3-8 cycloalkyl ring, C 5-8 cycloalkenyl ring, or five to seven membered heterocyclyl wherein said cycloalkyl, cycloalkenyl and heterocyclyl groups are optionally substituted with one or two substitutents independently selected from C 1-6 alkyl, halo, hydroxyalkyl, hydroxy, alkoxy or keto;
  • R 5 is selected from hydrogen or C 1-6 alkyl substituted with 1-6 halo
  • R 6 is aryl, heteroaryl, C 1-6 haloalkyl, arylalkyl or heteroarylalkyl, wherein said aryl, heteroaryl, arylalkyl and heteroarylalkyl groups are optionally substituted with one,
  • each D is independently C 1-3 alkyl, C 2-3 alkenyl, C 2-3 alkynyl, aryl, heteroaryl, C 3-8 cycloalkyl or heterocyclyl wherein each said aryl, heteroaryl, cycloalkyl and heterocyclyl groups, which may be monocyclic or bicyclic, is optionally substituted on either the carbon or the heteroatom with one to five substituents independently selected from C 1-6 alkyl, haloalkyl, halo, keto, alkoxy, —SR 9 , —SR 12 , —OR 9 , —OR 12 , N(R 12 ) 2 , —SO 2 R 9 , or —SO 2 R 10 ;
  • R 7 is hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkyloxy, halo, nitro, cyano, aryl, heteroaryl, C 3-8 cycloalkyl, heterocyclyl, —C(O)OR 10 , —C(O)OSi[CH(CH 3 ) 2 ] 3 , —OR 9 , —OR 10 , —C(O)R 10 , —R 10 C(O)R 9 , —C(O)R 9 , —C(O)N(R a )(R b ), —C(O)N(R 12 )(R 12 ), —C(O)N(R 10 )(R 11 ), —C(R 10 )(R 11 )OH, —SR 12 , —SR 9 , —R 10 SR 9 , —R 9 , —C(R 9 ) 3
  • R 8 is hydrogen or C 1-6 alkyl
  • R 4 and R 8 can be taken together with any of the atoms to which they may be attached or are between them to form a 4-10 membered heterocyclyl ring system wherein said ring system, which may be monocyclic or bicyclic, is optionally substituted with one or two substituents independently selected from C 1-6 alkyl, halo, hydroxyalkyl, hydroxy, keto, —OR 10 , —SR 10 or —N(R 10 ) 2 ;
  • R 9 is selected from the group consisting of hydrogen, aryl, aryl(C 1-4 ) alkyl, heteroaryl, heteroaryl(C 1-4 )alkyl, C 3-8 cycloalkyl, C 3-8 cycloalkyl(C 1-4 )alkyl, and heterocyclyl(C 1-4 )alkyl wherein said groups can be optionally substituted with one, two, or three substituents independently selected from halo, alkoxy or —SO 2 R 12 ;
  • R 10 is hydrogen or C 1-6 alkyl
  • R 11 is hydrogen or C 1-6 alkyl
  • R 12 is hydrogen or C 1-6 alkyl which is optionally substituted with one, two, or three substituents independently selected from halo, alkoxy, cyano, —NR 10 or —SR 10 ;
  • R a is hydrogen, C 1-6 alkyl, (C 1-6 alkyl)aryl, (C 1-6 alkyl)hydroxyl, —O(C 1-6 alkyl), hydroxyl, halo, aryl, heteroaryl, C 3-8 cycloalkyl, heterocyclyl, wherein said alkyl, aryl, heteroaryl, C 3-8 cycloalkyl and heterocyclyl can be optionally substituted on either the carbon or the heteroatom with one, two, or three substituents independently selected from C 1-6 alkyl or halo;
  • R b is hydrogen, C 1-6 alkyl, (C 1-6 alkyl)aryl, (C 1-6 alkyl)hydroxyl, alkoxyl, hydroxyl, halo, aryl, heteroaryl, C 3-8 cycloalkyl, heterocyclyl,wherein said alkyl, aryl, heteroaryl, C 3-8 cycloalkyl and heterocyclyl can be optionally substituted on either the carbon or the heteroatom with one, two, or three substituents independently selected from C 1-6 alkyl or halo;
  • R a and R b can be taken together with the carbon atom to which they are attached or are between them to form a C 3-8 cycloalkyl ring or C 3-8 heterocyclyl ring wherein said 3-8 membered ring system may be optionally substituted with one or two substituents independently selected from C 1-6 alkyl and halo;
  • R c is hydrogen or C 1-6 alkyl which is optionally substituted with one, two, or three substituents independently selected from halo or —OR 9 ;
  • R d is hydrogen or C 1-6 alkyl which is optionally substituted with one, two, or three substituents independently selected from halo or —OR 9 ;
  • R c and R d can be taken together with the nitrogen atom to which they are attached or are between them to form a C 3-8 heterocyclyl ring which is optionally substituted with one or two substituents independently selected from C 1-6 alkyl, halo hydroxyalkyl, hydroxy, alkoxy or keto;
  • n is independently selected from an integer from one to three;
  • each m is independently selected from an integer from zero to two;
  • R 1 and R 2 are each hydrogen.
  • R 1 and R 2 when on the same carbon atom, can be taken together with the carbon atom to which they are attached to form a 3-8 membered cycloalkyl ring system wherein said ring system is optionally substituted with C 1-6 alkyl, hydroxyalkyl and halo.
  • ring systems that can be formed include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • a preferred embodiment is when cyclopropyl is formed.
  • R 1 and R 2 together with the carbon atom to which they are attached to form a 3-8 membered heterocyclyl ring system wherein said ring system is optionally substituted with C 1-6 alkyl, hydroxyalkyl or haloalkyl.
  • ring systems that can be formed include piperidinyl, pyrrolidinyl, or tetrahydropyranyl.
  • R 3 and R 4 are each independently C 1-4 alkyl or H.
  • R 3 is isobutyl or n-propyl and R 4 is H, more preferably R 3 is n-propyl.
  • R 3 is C 1-6 alkyl wherein said alkyl is substituted with C 3-6 cycloalkyl or halo.
  • R 3 is 2-fluoro-2-methylpropyl, 2-trifluoromethylpropyl, 3-fluoro-2-(2-fluoromethyl)propyl, 2,2-difluoroethyl, 2,2-difluoropropyl, 3,3,3-trifluoropropyl, or 2,2-dichloroethyl and R 4 is hydrogen. More preferably R 3 is 2-fluoro-2-methylpropyl.
  • R 3 and R 4 taken together with the carbon atom to which they are attached to form C 3-8 cycloalkyl ring, C 5-8 cycloalkenyl ring, or five to seven membered heterocyclyl wherein said cycloalkyl, cycloalkenyl and heterocyclyl groups are optionally substituted with C 1-6 alkyl, halo, hydroxyalkyl, hydroxy, alkoxy or keto.
  • ring systems that can be formed include, but are not limited to the following, keeping in mind that the heterocycle is optionally substituted with one or more substituents as described above: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. In a class of the embodiment cyclohexyl is formed.
  • R 5 is C 1-6 alkyl substituted with 1-6 halo and R 6 is C 1-6 alkyl substituted with 1-6 halo.
  • R 5 is hydrogen and R 6 is C 1-6 alkyl substituted with 1-6 halo.
  • R 5 is hydrogen and R 6 is C 1-6 alkyl substituted with 1-6 fluoro.
  • R 5 is hydrogen and R 6 is C 1-3 alkyl substituted with 3 fluoro.
  • R 5 is hydrogen and R 6 is trifluoromethyl or 3,3,3,2,2-pentafluoroethyl, more preferably R 6 is trifluoromethyl.
  • R 5 is hydrogen and R 6 is aryl or heteoaryl, wherein said aryl and heteroaryl are optionally substituted with halo or —SO 2 R 12 .
  • R 1 and R 2 taken together with the carbon atom to which they are attached to form cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, more preferably cyclopropyl;
  • R 3 is n-propyl, isobutyl, 2-fluoro-2-methylpropyl, 2-trifluoromethylpropyl, 3-fluoro-2-(2-fluoromethyl)propyl, 2,2-difluoroethyl, 2,2-difluoropropyl, 3,3,3-trifluoropropyl, or 2,2-dichloroethyl;
  • R 4 and R 5 are hydrogen; and
  • R 6 is C 1-6 alkyl substituted with 1-6 halo; preferably R 6 is C 1-3 alkyl substituted with 3 fluoro; more preferably, R 6 is trifluoromethyl or 3,3,3,2,2-pentafluoroethyl, most
  • n is 1 where D is heteroaryl which is optionally substituted with halo or phenyl which is substituted with hydroxyalkyl, -COR 10 (where R 10 is C 1-6 alkyl) or —SO 2 R 12 or D is phenyl which is optionally substituted with halo, —CONR a R b (where R a is hydrogen or C 1-6 alkyl, and R b is hydrogen, C 1-6 alkyl, cycloalkyl or C 1-6 alkoxy or R a and R b together with the nitrogen atom to which they are attached form heterocylyl wherein said heterocyclyl is optionally substituted with alkyl, hydroxyalkyl, or haloalkyl), —SO 2 R 12 (where R 12 is C 1-6 alkyl), —COOR 10
  • n is 2 and each D is phenyl wherein the second phenyl is attached at the 4-position of the first phenyl ring (phenyl attached to carbon carrying the R 5 and R 6 groups) and further wherein each phenyl is optionally substituted with one or two substituents independently selected from C 1-6 alkyl, halo, hydroxy, alkoxy, haloalkyl, haloalkoxy or —SO 2 R 12 (where R 12 is C 1-6 alkyl) and the second phenyl is additionally substituted with R 7 .
  • each D is phenyl wherein the second phenyl is attached at the 4-position of the first phenyl ring and the second phenyl is optionally substituted with R 7 which is located at the 4-position of the phenyl ring and is —SO 2 R 12 (where R 12 is C 1-6 alkyl which is optionally substituted with hydroxy or halo), —SO 2 NR c R d (where R c and R d are independently hydrogen or C 1-6 alkyl or R c and R d together with the nitrogen atom to which they are attached form a heterocyclyl ring), —SR 12 (where R 12 is C 1-6 alkyl), —SOR 12 (where R 12 is C 1-6 alkyl), —NHCOR 10 (where R 10 is C 1-6 alkyl), —NR 10 R 11 (where R 10 and R 11 are C 1-6 alkyl), —SO 2 NHCOR 10 , heteroaryl, halo, —COOR 10 (where R 10
  • the second phenyl is substituted with with R 7 at the 4-position wherein R 7 is —SOR 12 , —SO 2 R 12 where R 12 is C 1-6 alkyl (preferably methyl) or —SO m NR c R d where R c and R d are independently hydrogen or alkyl or R c and R d together form heterocyclyl, and m is an integer from zero to two.
  • R 7 is methylsulfonyl, N-methylaminosulfonyl, aminosulfonyl, or morpholin-4-ylsulfonyl.
  • n is 2 where the first D (D attached to carbon carrying the R 5 and R 6 groups) is phenyl and the second D is heterocyclyl (preferably morpholin-4-yl, piperazin-1-yl or piperidin-4-yl) which is optionally substituted with cycloalkyl, heteroaryl, C 1-6 alkyl or hydroxyalkyl, more preferably cyclopropyl, methyl, ethyl, or hydroxyethyl and said heterocyclyl ring is attached at the 4-position of the phenyl ring.
  • heterocyclyl preferably morpholin-4-yl, piperazin-1-yl or piperidin-4-yl
  • n is 2 where the first D (D attached to carbon carrying the R 5 and R 6 groups) is phenyl and the second D is heteroaryl which is substituted with one or two substituents independently selected from hydroxyalkyl, —SO 2 R 12 (where R 12 is C 1-6 alkyl), C 1-6 alkyl, halo, haloalkyl, amino, or —OR 10 .
  • n is 3 wherein the first and the second Ds are phenyl and the third D is heterocyclyl and are optionally substituted as defined above. More preferably first and the second Ds are phenyl wherein the second phenyl is attached at the 4-position of the first phenyl and the heterocyclyl is morpholin-4-yl, pyrrolidin-1-yl, piperidin-1-yl, piperidin-4-yl or piperazin-1-yl which are substituted with R 7 .
  • R 7 is hydrogen, alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, COOR 10 or —SO 2 R 2 (where R 12 is C 1-6 alkyl).
  • R 1 and R 2 taken together with the carbon atom to which they are attached to form cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, more preferably cyclopropyl;
  • R 3 and R 4 taken together with the carbon atom to which they are attached form C 3-8 cycloalkyl ring, C 5-8 cycloalkenyl ring, or five to seven membered heterocyclyl wherein said cycloalkyl, cycloalkenyl and heterocyclyl groups are optionally substituted with C 1-6 alkyl, halo, hydroxyalkyl, hydroxy, alkoxy or keto.
  • ring systems that can be formed include, but are not limited to the following, keeping in mind that the heterocycle is optionally substituted with one or more substituents as described above: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, tetrahydrofuran-4-yl, piperidin-4-yl.
  • R 3 and R 4 taken together with the carbon atom to which they are attached form cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl.
  • a more preferred embodiment is when R 3 and R 4 taken together with the carbon atom to which they are attached form cyclohexyl is formed.
  • R 5 are hydrogen; and R 6 is C 1-6 alkyl substituted with 1-6 halo; preferably R 6 is C 1-3 alkyl substituted with 3 fluoro; more preferably, R 6 is trifluoromethyl or 3,3,3,2,2-pentafluoroethyl, most preferably trifluoromethyl.
  • a particularly preferred embodiment is that wherein n is 1.
  • Another particularly preferred embodiment is that wherein n is 2.
  • Yet another particularly preferred embodiments is that wherein n is 3.
  • n is 1 where D is heteroaryl which is optionally substituted with halo or phenyl with is substituted with hydroxyalkyl, —COR 10 (where R 10 is C 1-6 alkyl) or —SO 2 R 12 or D is phenyl which is optionally substituted with halo, —CONR a R b (where R a is hydrogen or C 1-6 alkyl, and R b is hydrogen, C 1-6 alkyl, cycloalkyl or C 1-6 alkoxy or R a and R b together with the nitrogen atom to which they are attached form heterocylyl wherein said heterocyclyl is optionally substituted with alkyl or haloalkyl), —SO 2 R 12 (where R 12 is C 1-6 alkyl), —COOR 10 , alkynyl substituted with hydroxy, alkenyl substituted with hydroxy, alkyl optionally substituted with hydroxy, —OR 10 , —CR 10 R 11 SC 10 R 11 R 11 R
  • n is 2 and each D is phenyl wherein the second phenyl is attached at the 4-position of the first phenyl ring (phenyl attached to carbon carrying the R 5 and R 6 groups) and further wherein each phenyl is optionally substituted with one or two substituents independently selected from C 1-6 alkyl, halo, hydroxy, alkoxy, haloalkyl, haloalkoxy and the second phenyl is additionally substituted with R 7 .
  • each D is phenyl wherein the second phenyl is attached at the 4-position of the first phenyl ring and the second phenyl is optionally substituted with R 7 which is located at the 4-position of the phenyl ring and is —SO 2 R 12 (where R 12 is C 1-6 alkyl which is optionally substituted with halo), —SO 2 NR c R d (where R c and R d are independently hydrogen or C 1-6 alkyl or R c and R d together with the nitrogen atom to which they are attached form a heterocyclyl ring), —SR 12 (where R 12 is C 1-6 alkyl), —NHCOR 9 (where R 9 is C 1-6 alkyl), —NR 10 R 11 (where R 10 and R 11 are C 1-6 alkyl), heteroaryl, halo, —COOR 10 (where R 10 is hydrogen or C 1-6 alkyl 1), —OR 9 (where R 9 is hydrogen or aryl), aryl substitute
  • the second phenyl is substituted with with R 7 at the 4-position wherein R 7 is —SO 2 R 12 where R 12 is C 1-6 alkyl (preferably methyl) or —SO m NR c R d where R c and R d are independently hydrogen or alkyl or R c and R d together form heterocyclyl, and m is an integer from zero to two.
  • R 7 is methylsulfonyl, N-methylaminosulfonyl, aminosulfonyl, or morpholin-4-ylsulfonyl.
  • n is 2 where the first D (D attached to carbon carrying the R 5 and R 6 groups) is phenyl and the second D is heterocyclyl (preferably piperazin-1-yl or piperidin-4-yl) substituted with cycloalkyl, C 1-6 alkyl or hydroxyalkyl, more preferably cyclopropyl, methyl, ethyl, or hydroxyethyl and said heterocyclyl ring is attached at the 4-position of the phenyl ring.
  • heterocyclyl preferably piperazin-1-yl or piperidin-4-yl
  • n is 2 where the first D (D attached to carbon carrying the R 5 and R 6 groups) is phenyl and the second D is heteroaryl which is substituted with one or two substituents independently selected from hydroxyalkyl, —SO 2 R 12 (where R 12 is C 1-6 alkyl), C 1-6 alkyl, halo, or —OR 10 .
  • n is 3 wherein the first and the second Ds are phenyl and the third D is heterocyclyl and are optionally substituted as defined above. More preferably first and the second Ds are phenyl wherein the second phenyl is attached at the 4-position of the first phenyl and the heterocyclyl is morpholin-4-yl, pyrrolidin-1-yl, piperidin-1-yl, piperidin-4-yl or piperazin-1-yl which are substituted with R 7 .
  • R 7 is hydrogen, alkyl, hydroxyalkyl, haloalkyl or cycloalkyl.
  • R 5 is hydrogen and R 6 is aryl optionally substituted with one, two, or three substituents independently selected from halo, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, haloalkoxy, —SR 9 , —SR 12 , —SOR 9 , —SOR 12 , —SO 2 R 9 , —SO 2 R 12 , —SO 2 CH(R 12 )(R 11 ), —OR 12 , —N(R 10 )(R 11 ), cyano, or aryl which is optionally substituted with —SO 2 R 12 .
  • phenyl substituted with C 1-6 alkyl, halo, haloalkyl, or haloalkoxy within this embodiment, a preferred embodiment is that wherein R 1 and R 2 are each hydrogen. Within this embodiment, another preferred embodiment is that wherein R 1 and R 2 taken together with the carbon atom to which they are attached to form a 3-8 membered cycloalkyl or heterocyclyl ring system wherein said ring system is optionally substituted with C 1-6 alkyl, hydroxyalkyl and halo.
  • Preferable ring systems that can be formed include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, more preferably cyclopropyl.
  • R 3 is C 1-4 alkyl and R 4 is H.
  • R 3 is n-propyl or isobutyl and R 4 is H.
  • R 3 is 2-fluoro-2-methylpropyl, 2-trifluoromethylpropyl, 3-fluoro-2-(2-fluoromethyl)propyl, 2,2-difluoroethyl, 2,2-difluoropropyl, 3,3,3-trifluoropropyl, or 2,2-dichloroethyl; and R 4 is hydrogen.
  • R 3 and R 4 can be taken together with the carbon atom to which they are attached to form C 3-8 cycloalkyl ring, C 5-8 cycloalkenyl ring, or five to seven membered heterocyclyl wherein said cycloalkyl, cycloalkenyl and heterocyclyl groups are optionally substituted with C 1-6 alkyl, halo, hydroxyalkyl, hydroxy, alkoxy or keto.
  • ring systems that can be formed include, but are not limited to the following, keeping in mind that the heterocycle is optionally substituted with one or more substituents as described above: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • a preferred embodiment is when cyclohexyl is formed.
  • n is 1 where D is heteroaryl which is optionally substituted with halo or phenyl with is substituted with hydroxyalkyl, —COR 10 (where R is C 1-6 alkyl) or —SO 2 R 12 or D is phenyl which is optionally substituted with halo, —CONR a R b (where R a is hydrogen or C 1-6 alkyl, and R b is hydrogen, C 1-6 alkyl, cycloalkyl or C 1-6 alkoxy or R a and R b together with the nitrogen atom to which they are attached form heterocylyl wherein said heterocyclyl is optionally substituted with alkyl or haloalkyl), —SO 2 R 12 (where R 12 is C 1-6 alkyl), —COOR 10 , alkyn
  • n is 2 and each D is phenyl wherein the second phenyl is attached at the 4-position of the first phenyl ring (phenyl attached to carbon carrying the R 5 and R 6 groups) and further wherein each phenyl is optionally substituted with one or two substituents independently selected from C 1-6 alkyl, halo, hydroxy, alkoxy, haloalkyl, haloalkoxy and the second phenyl is additionally substituted with R 7 .
  • each D is phenyl wherein the second phenyl is attached at the 4-position of the first phenyl ring and the second phenyl is optionally substituted with R 7 which is located at the 4-position of the phenyl ring and is —SO 2 R 12 (where R 12 is C 1-6 alkyl which is optionally substituted with halo), —SO 2 NR c R d (where R c and R d are independently hydrogen or C 1-6 alkyl or R c and R d together with the nitrogen atom to which they are attached form a heterocyclyl ring), —SR 12 (where R 12 is C 1-6 alkyl), —NHCOR 9 (where R 9 is C 1-6 alkyl), —NR 10 R 11 (where R 10 and R 11 are C 1-6 alkyl), heteroaryl, halo, —COOR 10 (where R 10 is hydrogen or C 1-6 alkyl 1), —OR 9 (where R 9 is hydrogen or aryl), aryl substitute
  • the second phenyl is substituted with with R 7 at the 4-position wherein R 7 is —SO 2 R 12 where R 12 is C 1-6 alkyl (preferably methyl) or —SO m NR c R d where R c and R d are independently hydrogen or alkyl or R c and R d together form heterocyclyl, and m is an integer from zero to two.
  • R 7 is methylsulfonyl, N-methylaminosulfonyl, aminosulfonyl, or morpholin-4-ylsulfonyl.
  • n is 2 where the first D (D attached to carbon carrying the R 5 and R 6 groups) is phenyl and the second D is heterocyclyl (preferably piperazin-1-yl or piperidin-4-yl) substituted with cycloalkyl, C 1-6 alkyl or hydroxyalkyl, more preferably cyclopropyl, methyl, ethyl, or hydroxyethyl and said heterocyclyl ring is attached at the 4-position of the phenyl ring.
  • heterocyclyl preferably piperazin-1-yl or piperidin-4-yl
  • n is 2 where the first D (D attached to carbon carrying the R 5 and R 6 groups) is phenyl and the second D is heteroaryl which is substituted with one or two substituents independently selected from hydroxyalkyl, —SO 2 R 12 (where R 12 is C 1-6 alkyl), C 1-6 alkyl, halo, or —OR 10 .
  • n is 3 wherein the first and the second Ds are phenyl and the third D is heterocyclyl and are optionally substituted as defined above. More preferably first and the second Ds are phenyl wherein the second phenyl is attached at the 4-position of the first phenyl and the heterocyclyl is morpholin-4-yl, pyrrolidin-1-yl, piperidin-1-yl, piperidin-4-yl or piperazin-1-yl which are substituted with R 7 .
  • R 7 is hydrogen, alkyl, hydroxyalkyl, haloalkyl or cycloalkyl.
  • R 5 is hydrogen and R 6 is heteroaryl optionally substituted with C1-6alkyl, halo, haloalkyl, or haloalkoxy.
  • R 6 is thiazolyl, pyridinyl, tetrazolyl, thienyl, or furanyl, optionally substituted with C 1-4 alkyl or halo.
  • a preferred embodiment is that wherein R 1 and R 2 are each hydrogen.
  • R 1 and R 2 taken together with the carbon atom to which they are attached to form a 3-8 membered cycloalkyl or heterocyclyl ring system wherein said ring system is optionally substituted with C 1-6 alkyl, hydroxyalkyl and halo.
  • Preferable ring systems that can be formed include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, more preferably cyclopropyl.
  • R 3 is C 1-4 alkyl and R 4 is H.
  • R 3 is n-propyl or isobutyl and R 4 is H.
  • R 4 is H.
  • another even more preferred embodiment is that wherein R 3 is 2-fluoro-2-methylpropyl, 2-trifluoromethylpropyl, 3-fluoro-2-(2-fluoromethyl)propyl, 2,2-difluoroethyl, 2,2-difluoropropyl, 3,3,3-trifluoropropyl, or 2,2-dichloroethyl; and R 4 is hydrogen.
  • R 3 and R 4 can be taken together with the carbon atom to which they are attached to form C 3-8 cycloalkyl ring, C 5-8 cycloalkenyl ring, or five to seven membered heterocyclyl wherein said cycloalkyl, cycloalkenyl and heterocyclyl groups are optionally substituted with C 1-6 alkyl, halo, hydroxyalkyl, hydroxy, alkoxy or keto.
  • ring systems that can be formed include, but are not limited to the following, keeping in mind that the heterocycle is optionally substituted with one or more substituents as described above: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • a preferred embodiment is when cyclohexyl is formed.
  • n is 1 where D is heteroaryl which is optionally substituted with halo or phenyl with is substituted with hydroxyalkyl, —COR 10 (where R 10 is C 1-6 alkyl) or —SO 2 R 12 or D is phenyl which is optionally substituted with halo, —CONR a R b (where R a is hydrogen or C 1-6 alkyl, and R b is hydrogen, C 1-6 alkyl, cycloalkyl or C 1-6 alkoxy or R a and R b together with the nitrogen atom to which they are attached form heterocylyl wherein said heterocyclyl is optionally substituted with alkyl or haloalkyl), —SO 2 R 12 (where R 12 is C 1-6 alkyl), —COOR 10 , alky
  • n is 2 and each D is phenyl wherein the second phenyl is attached at the 4-position of the first phenyl ring (phenyl attached to carbon carrying the R 5 and R 6 groups) and further wherein each phenyl is optionally substituted with one or two substituents independently selected from C 1-6 alkyl, halo, hydroxy, alkoxy, haloalkyl, haloalkoxy and the second phenyl is additionally substituted with R 7 .
  • each D is phenyl wherein the second phenyl is attached at the 4-position of the first phenyl ring and the second phenyl is optionally substituted with R 7 which is located at the 4-position of the phenyl ring and is —SO 2 R 2 (where R 12 is C 1-6 alkyl which is optionally substituted with halo), —SO 2 NR c R d (where R c and R d are independently hydrogen or C 1-6 alkyl or R c and R d together with the nitrogen atom to which they are attached form a heterocyclyl ring), —SR 12 (where R 12 is C 1-6 alkyl), —NHCOR 9 (where R 9 is C 1-6 alkyl), —NR 10 R 11 (where R 10 and R 11 are C 1-6 alkyl), heteroaryl, halo, —COOR 10 (where R 10 is hydrogen or C 1-6 alkyl 1), —OR 9 (where R 9 is hydrogen or aryl), aryl substitute
  • the second phenyl is substituted with with R 7 at the 4-position wherein R 7 is —SO 2 R 12 where R 12 is C 1-6 alkyl (preferably methyl) or —SO m NR c R d where R c and R d are independently hydrogen or alkyl or R c and R d together form heterocyclyl, and m is an integer from zero to two.
  • R 7 is methylsulfonyl, N-methylaminosulfonyl, aminosulfonyl, or morpholin-4-ylsulfonyl.
  • n is 2 where the first D (D attached to carbon carrying the R 5 and R 6 groups) is phenyl and the second D is heterocyclyl (preferably piperazin-1-yl or piperidin-4-yl) substituted with cycloalkyl, C 1-6 alkyl or hydroxyalkyl, more preferably cyclopropyl, methyl, ethyl, or hydroxyethyl and said heterocyclyl ring is attached at the 4-position of the phenyl ring.
  • heterocyclyl preferably piperazin-1-yl or piperidin-4-yl
  • n is 2 where the first D (D attached to carbon carrying the R 5 and R 6 groups) is phenyl and the second D is heteroaryl which is substituted with one or two substituents independently selected from hydroxyalkyl, —SO 2 R 12 (where R 12 is C 1-6 alkyl), C 1-6 alkyl, halo, or —OR 10 .
  • n is 3 wherein the first and the second Ds are phenyl and the third D is heterocyclyl and are optionally substituted as defined above. More preferably first and the second Ds are phenyl wherein the second phenyl is attached at the 4-position of the first phenyl and the heterocyclyl is morpholin-4-yl, pyrrolidin-1-yl, piperidin-1-yl, piperidin-4-yl or piperazin-1-yl which are substituted with R 7 .
  • R 7 is hydrogen, alkyl, hydroxyalkyl, haloalkyl or cycloalkyl.
  • R 4 and R 8 can be taken together with any of the atoms to which they may be attached or are between them to form a 4-10 membered heterocyclyl ring system wherein said ring system, which may be monocyclic or bicyclic, is optionally substituted with C 1-6 alkyl, halo, hydroxyalkyl, hydroxy, keto, —OR 10 , —SR 10 or —N(R 10 ) 2 .
  • R 4 and R 8 are defined such that they can be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocyclyl with 5-7 members in each ring and optionally containing, in addition to the nitrogen, 1 or 2 additional heteroatoms selected from N, O and S, said heterocycle optionally substituted with one or more substituents selected from C 1-6 alkyl, halo; hydroxyalkyl, hydroxy, keto, —OR 10 , —SR 10 or —N(R 10 ) 2 .
  • R 4 and R 8 are defined such that they can be taken together with the nitrogen to which they are attached to form a 5 or 6 membered heterocyclyl ring system.
  • heterocycles examples include, but are not limited five or six membered rings containing at least one nitrogen, which is optionally substituted with one or more substituents as described above.
  • a preferred embodiment is when optionally substituted pyrolidinyl is formed.
  • R a and R b are defined such that they can be taken together with the carbon or nitrogen to which they are attached to form a monocyclic or bicyclic carbocycle or heterocycle with 5-7 members in each ring.
  • the heterocycle can optionally contain, in addition to the nitrogen, 1 or 2 additional heteroatoms selected from N, O and S.
  • Said carbocycle and heterocycle can be optionally substituted with one or more substituents selected from C 1-6 alkyl and halo.
  • Another embodiment of the present invention encompasses a process for preparing compounds of the present invention, comprising:
  • R 1 -R 6 and D are as defined as above, n 1 is an integer from 1-3, and X is halo, with a compound of formula (b):
  • n2 is an integer from 0 to 2 provided that n 1 and n2 together are an integer from 1-3, and Y is boronic acid or 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl; or
  • R 3 -R 7 , n, and D are as defined as above and Z is hydroxy, halo, or succinimido ester with a compound of formula (d):
  • Embodied by the present invention are methods for treating disorders related to abnormal bone resoprtion.
  • disorders include, but are not limited to, osteoporosis, glucocorticoid induced osteoporosis, Paget's disease, abnormally increased bone turnover, periodontal disease, tooth loss, bone fractures, rheumatoid arthritis, osteoarthritis, periprosthetic osteolysis, osteogenesis imperfecta, metastatic bone disease, hypercalcemia of malignancy, and multiple myeloma.
  • a preferred embodiment includes methods for treating osteoporosis and metastatic bone disease.
  • a more preferred embodiment includes methods for treating osteoporosis.
  • N 1 (cyanomethyl)-N 2 -[2,2,2-trifluoro-1-(4′-piperazin-1-yl-1,1′-biphenyl-4-yl)ethyl]-L-leucinamide;
  • N 1 (cyanomethyl)-N 2 -(2,2,2-trifluoro-1- ⁇ 4′-[4-(2-fluoroethyl)piperazin-1-yl]-1,1′-biphenyl-4-yl ⁇ ethyl)-L-leucinamide;
  • N 1 (cyanomethyl)-3-(1-methylcyclopropyl)-N 2 - ⁇ (1S)-2,2,2-trifluoro-1-[4′-(methylthio)-1,1′-biphenyl-4-yl]ethyl ⁇ -L-alaninamide;
  • N 1 -(cyanomethyl)-N 2 [(1S)-2,2,2-trifluoro-1-(4-pyrazin-2-ylphenyl)ethyl]-L-leucinamide;
  • N 2 [0360] N 2 -[(1S)-1-(1,1′-biphenyl-4-yl)-2,2,2-trifluoroethyl]-N 1 -(1-cyanocyclopropyl)-L-leucinamide;
  • N 2 - ⁇ (1S)-1-[4′-(aminosulfonyl)-1,1′-biphenyl-4-yl]-2,2,2-trifluoroethyl ⁇ -N 1 -(1-cyanocyclopropyl)-4-fluoro-L-leucinamide;
  • N 2 [0540] N 2 -[(1S)-1-(4′-acetyl-1,1′-biphenyl-4-yl)-2,2,2-trifluoroethyl]-N 1 -(1-cyanocyclopropyl)-4-fluoro-L-leucinamide;
  • N 2 [0541] N 2 -[(1S)-1-(2′-acetyl-1,1′-biphenyl-4-yl)-2,2,2-trifluoroethyl]-N 1 -(1-cyanocyclopropyl)-4-fluoro-L-leucinamide;
  • N 2 [0578] N 2 -[(1S)-1-(4′-acetyl-1,1′-biphenyl-4-yl)-2,2,2-trifluoroethyl]-N 1 -(1-cyanocyclopropyl)-L-leucinamide;
  • N 1 [0583] N 1 -[(1S)-1-cyano-3-(methylsulfonyl)propyl]-N 2 - ⁇ (1S)-2,2,2-trifluoro-1-[4′-(methylsulfonyl)-1,1′-biphenyl-4-yl]ethyl ⁇ -L-leucinamide;
  • N 2 [0587] N 2 -[(1S)-1-(4′-acetyl-1,1′-biphenyl-4-yl)-2,2,2-trifluoroethyl]-N 1 -(1-cyanocyclopropyl)-L-leucinamide;
  • N 1 [(1S)-1-cyano-3-(methylsulfonyl)propyl]-N 2 - ⁇ (1S)-2,2,2-trifluoro-1-[4′-(methylsulfonyl)-1,1′-biphenyl-4-yl]ethyl ⁇ -L-leucinamide;
  • compositions which is comprised of a compound of Formula I as described above and a pharmaceutically acceptable carrier.
  • the invention is also contemplated to encompass a pharmaceutical composition which is comprised of a pharmaceutically acceptable carrier and any of the compounds specifically disclosed in the present application.
  • the compounds of the present invention are inhibitors of cathepsins and are therefore useful to treat or prevent cathepsin dependent diseases or conditions in mammals, preferably humans.
  • the compounds of the present invention are inhibitors of Cathepsin K and are therefore useful to treat or prevent Cathepsin K dependent diseases or conditions in mammals, preferably humans.
  • Cathepsin dependent diseases or conditions refers to pathologic conditions that depend on the activity of one or more cathepsins.
  • Cathepsin K dependent diseases or conditions refers to pathologic conditions that depend on the activity of Cathepsin K.
  • Diseases associated with Cathepsin K activities include osteoporosis, glucocorticoid induced osteoporosis, Paget's disease, abnormally increased bone turnover, periodontal disease, tooth loss, bone fractures, rheumatoid arthritis, osteoarthritis, periprosthetic osteolysis, osteogenesis imperfecta, metastatic bone disease, hypercalcemia of malignancy, and multiple myeloma.
  • the required therapeutic amount will vary according to the specific disease and is readily ascertainable by those skilled in the art. Although both treatment and prevention are contemplated by the scope of the invention, the treatment of these conditions is the preferred use.
  • An embodiment of the invention is a method of inhibiting cathepsin activity in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of any of the compounds or any of the pharmaceutical compositions described above.
  • a class of the embodiment is the method wherein the cathepsin activity is cathepsin K activity.
  • Another embodiment of the invention is a method of treating or preventing cathepsin dependent conditions in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of any of the compounds or any of the pharmaceutical compositions described above.
  • a class of the embodiment is the method wherein the cathepsin activity is cathepsin K activity.
  • Another embodiment of the invention is a method of inhibiting bone loss in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of any of the compounds or any of the pharmaceutical compositions described above.
  • Another embodiment of the invention is a method of reducing bone loss in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of any of the compounds or any of the pharmaceutical compositions described above.
  • the utility of cathepsin K inhibitors in the inhibition of bone resorption is known in the literature, see Stroup, G. B., Lark, M. W., Veber, D F., Bhattacharrya, A., Blake, S., Dare, L. C., Erhard, K.
  • Another embodiment of the invention is a method of treating or preventing osteoporosis in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of any of the compounds or any of the above pharmaceutical compositions described above.
  • the utility of cathepsin K inhibitors in the treatment or prevention of osteoporosis is known in the literature, see Saftig, P., Hunziker, E., Wehmeyer, O., Jones, S., Boyde, A., Rommerskirch, W., Moritz, J. D., Schu, P., and Vonfigura, K. Impaired osteoclast bone resorption leads to osteoporosis in cathepsin K-deficient mice. Proc. Natl. acad. Sci. USA 95:13453-13458; 1998.
  • Another embodiment of the invention is a method of treating or preventing rheumatoid arthritic condition in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of any of the compounds or any of the pharmaceutical compositions described above.
  • RA rheumatoid arthritis
  • cathepsin K positive osteoclasts are the cell types that mediate the focal bone resorption associated with rheumatoid synovial lesion, see Hou, W -S, Li, W, Keyszer, G, Weber, E, Levy, R, Klein, M J, Gravallese, E M, Goldring, S R, Bromme, D, “Comparision of Cathepsin K and S expression within the Rheumatoid and Osteoarthritic Synovium”, Arthritis Rheumatism 2002; 46: 663-74.
  • generalized bone loss is a major cause of morbility associated with severe RA.
  • Another embodiment of the invention is a method of treating or preventing-the progression of osteoarthritis in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of any of the compounds or any of the pharmaceutical compositions described above.
  • osteoarthritis OA
  • cathepsin K inhibitors in the treatment or prevention of osteoarthritis as described in this invention thus comprise of two different mechanisms, one is on the inhibition of osteoclast-driven subchondral bone turnover, and two is on the direct inhibition of collagen type II degeneration in the synovium and cartilage of patients with OA.
  • Another embodiment of the invention is a method treating cancer in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of any of the compounds or any of the pharmaceutical compositions described above.
  • cathepsin K is expressed in human breast carcinoma, see Littlewood-Evans A J, Bilbe G, Bowler W B, Farley D, Wlodarski B, Kokubo T, Inaoka T, Sloane J, Evans D B, Gallagher J A, “The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma.” Cancer Res Dec. 1, 1997;57(23):5386-90.
  • Exemplifying the invention is the use of any of the compounds described above in the preparation of a medicament for the treatment and/or prevention of osteoporosis in a mammal in need thereof. Still further exemplifying the invention is the use of any of the compounds described above in the preparation of a medicament for the treatment and/or prevention of: bone loss, bone resorption, bone fractures, metastatic bone disease and/or disorders related to cathepsin functioning.
  • the compounds of this invention may be administered to mammals, preferably humans, either alone or, preferably, in combination with pharmaceutically acceptable carriers or diluents, optionally with known adjuvants, such as alum, in a pharmaceutical composition, according to standard pharmaceutical practice.
  • the compounds can be administered orally or parenterally, including the intravenous, intramuscular, intraperitoneal, subcutaneous, rectal and topical routes of administration.
  • carriers which are commonly used include lactose and corn starch, and lubricating agents, such as magnesium stearate, are commonly added.
  • useful diluents include lactose and dried corn starch.
  • the selected compound may be administered, for example, in the form of tablets or capsules, or as an aqueous solution or suspension.
  • the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium.
  • the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
  • suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture.
  • suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like.
  • Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
  • Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.
  • aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavoring agents may be added.
  • sterile solutions of the active ingredient are usually prepared, and the pH of the solutions should be suitably adjusted and buffered.
  • the total concentration of solutes should be controlled in order to render the preparation isotonic.
  • the compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
  • Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.
  • Compounds of the present invention may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled.
  • the compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers.
  • Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxy-ethylaspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues.
  • the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polyactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and crosslinked or amphipathic block copolymers of hydrogels.
  • a drug for example, polylactic acid, polyglycolic acid, copolymers of polyactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and crosslinked or amphipathic block copolymers of hydrogels.
  • the instant compounds are also useful in combination with known agents useful for treating or preventing osteoporosis, glucocorticoid induced osteoporosis, Paget's disease, abnormally increased bone turnover, periodontal disease, tooth loss, bone fractures, rheumatoid arthritis, osteoarthritis, periprosthetic osteolysis, osteogenesis imperfecta, metastatic bone disease, hypercalcemia of malignancy, and multiple myeloma.
  • Combinations of the presently disclosed compounds with other agents useful in treating or preventing osteoporosis or other bone disorders are within the scope of the invention.
  • a person of ordinary skill in the art would be able to discern which combinations of agents would be useful based on the particular characteristics of the drugs and the disease involved.
  • Such agents include the following: an organic bisphosphonate; an estrogen receptor modulator; an androgen receptor modulator; an inhibitor of osteoclast proton ATPase; an inhibitor of HMG-CoA reductase; an integrin receptor antagonist; an osteoblast anabolic agent, such as PTH; and the pharmaceutically acceptable salts and mixtures thereof.
  • a preferred combination is a compound of the present invention and an organic bisphosphonate.
  • Another preferred combination is a compound of the present invention and an estrogen receptor modulator.
  • Another preferred combination is a compound of the present invention and an androgen receptor modulator.
  • Another preferred combination is a compound of the present invention and an osteoblast anabolic agent.
  • Organic bisphosphonate includes, but is not limited to, compounds of the chemical formula
  • n is an integer from 0 to 7 and wherein A and X are independently selected from the group consisting of H, OH, halogen, NH 2 , SH, phenyl, C1-C30 alkyl, C3-C30 branched or cycloalkyl, bicyclic ring structure containing two or three N, C1-C30 substituted alkyl, C1-C10 alkyl substituted NH 2 , C3-C10 branched or cycloalkyl substituted NH 2 , C1-C10 dialkyl substituted NH 2 , C1-C10 alkoxy, C1-C10 alkyl substituted thio, thiophenyl, halophenylthio, C1-C10 alkyl substituted phenyl, pyridyl, furanyl, pyrrolidinyl, imidazolyl, imidazopyridinyl, and benzyl, such that both A and X
  • the alkyl groups can be straight, branched, or cyclic, provided sufficient atoms are selected for the chemical formula.
  • the C1-C30 substituted alkyl can include a wide variety of substituents, nonlimiting examples which include those selected from the group consisting of phenyl, pyridyl, furanyl, pyrrolidinyl, imidazonyl, NH 2 , C1-C 10 alkyl or dialkyl substituted NH 2 , OH, SH, and C1-C10 alkoxy.
  • the foregoing chemical formula is also intended to encompass complex carbocyclic, aromatic and hetero atom structures for the A and/or X substituents, nonlimiting examples of which include naphthyl, quinolyl, isoquinolyl, adamantyl, and chlorophenylthio.
  • salts include those selected from the group consisting alkali metal, alkaline metal, ammonium, and mono-, di-, tri-, or tetra-C1-C30-alkyl-substituted ammonium.
  • Preferred salts are those selected from the group consisting of sodium, potassium, calcium, magnesium, and ammonium salts. More preferred are sodium salts.
  • Non-limiting examples of derivatives include those selected from the group consisting of esters, hydrates, and amides.
  • bisphosphonate and “bisphosphonates”, as used herein in referring to the therapeutic agents of the present invention are meant to also encompass diphosphonates, biphosphonic acids, and diphosphonic acids, as well as salts and derivatives of these materials.
  • the use of a specific nomenclature in referring to the bisphosphonate or bisphosphonates is not meant to limit the scope of the present invention, unless specifically indicated. Because of the mixed nomenclature currently in use by those of ordinary skill in the art, reference to a specific weight or percentage of a bisphosphonate compound in the present invention is on an acid active weight basis, unless indicated otherwise herein.
  • the phrase “about 5 mg of a bone resorption inhibiting bisphosphonate selected from the group consisting of alendronate, pharmaceutically acceptable salts thereof, and mixtures thereof, on an alendronic acid active weight basis” means that the amount of the bisphosphonate compound selected is calculated based on 5 mg of alendronic acid.
  • Non-limiting examples of bisphosphonates useful herein include the following:
  • Alendronate also known as alendronate sodium or alendronate monosodium trihydrate
  • 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid monosodium trihydrate 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid monosodium trihydrate.
  • Nonlimiting examples of bisphosphonates include alendronate, cimadronate, clodronate, etidronate, ibandronate, incadronate, minodronate, neridronate, olpadronate, pamidronate, piridronate, risedronate, tiludronate, and zolendronate, and pharmaceutically acceptable salts and esters thereof.
  • a particularly preferred bisphosphonate is alendronate, especially a sodium, potassium, calcium, magnesium or ammonium salt of alendronic acid. Exemplifying the preferred bisphosphonate is a sodium salt of alendronic acid, especially a hydrated sodium salt of alendronic acid.
  • the salt can be hydrated with a whole number of moles of water or non whole numbers of moles of water. Further exemplifying the preferred bisphosphonate is a hydrated sodium salt of alendronic acid, especially when the hydrated salt is alendronate monosodium trihydrate.
  • the precise dosage of the organic bisphosphonate will vary with the dosing schedule, the particular bisphosphonate chosen, the age, size, sex and condition of the mammal or human, the nature and severity of the disorder to be treated, and other relevant medical and physical factors. Thus, a precise pharmaceutically effective amount cannot be specified in advance and can be readily determined by the caregiver or clinician. Appropriate amounts can be determined by routine experimentation from animal models and human clinical studies. Generally, an appropriate amount of bisphosphonate is chosen to obtain a bone resorption inhibiting effect, i.e. a bone resorption inhibiting amount of the bisphosphonate is administered.
  • an effective oral dose of bisphosphonate is typically from about 1.5 to about 6000 ⁇ g/kg body weight and preferably about 10 to about 2000 ⁇ g/kg of body weight.
  • alendronate monosodium trihydrate common human doses which are administered are generally in the range of about 2 mg/day to about 40 mg/day, preferably about 5 mg/day to about 40 mg/day.
  • presently approved dosages for alendronate monosodium trihydrate are 5 mg/day for preventing osteoporosis, 10 mg/day for treating osteoporosis, and 40 mg/day for treating Paget's disease.
  • the bisphosphonate can be administered at intervals other than daily, for example once-weekly dosing, twice-weekly dosing, biweekly dosing, and twice-monthly dosing.
  • alendronate monosodium trihydrate would be administered at dosages of 35 mg/week or 70 mg/week.
  • “Selective estrogen receptor modulators” refers to compounds which interfere or inhibit the binding of estrogen to the receptor, regardless of mechanism.
  • Examples of estrogen receptor modulators include, but are not limited to, estrogen, progestogen, estradiol, droloxifene, raloxifene, lasofoxifene, TSE-424, tamoxifen, idoxifene, LY353381, LY117081, toremifene, fulvestrant, 4-[7-(2,2-dimethyl-1-oxopropoxy-4-methyl-2-[4-[2-(1-piperidinyl)ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl-2,2-dimethylpropanoate, 4,4′-dihydroxybenzophenone-2,4-dinitrophenyl-hydrazone, and SH646.
  • An “estrogen receptor beta modulator” is a compound that selectively agonizes or antagonizes estrogen receptor beta (ER ⁇ ). Agonizing ER ⁇ increases transcription of the tryptophan hydroxylase gene (TPH, the key enzyme in serotonin synthesis) via an ER ⁇ mediated event. Examples of estrogen receptor beta agonists can be found in PCT International publication WO 01/82923, which published on Nov. 08, 2001, and WO 02/41835, which published on May 20, 2002, both of which are hereby incorporated by reference in their entirety.
  • Androgen receptor modulators refers to compounds which interfere or inhibit the binding of androgens to the receptor, regardless of mechanism.
  • Examples of androgen receptor modulators include finasteride and other 5 ⁇ -reductase inhibitors, nilutamide, flutamide, bicalutamide, liarozole, and abiraterone acetate.
  • An inhibitor of osteoclast proton ATPase refers to an inhibitor of the proton ATPase, which is found on the apical membrane of the osteoclast, and has been reported to play a significant role in the bone resorption process. This proton pump represents an attractive target for the design of inhibitors of bone resorption which are potentially useful for the treatment and prevention of osteoporosis and related metabolic diseases. See C. Farina et al., “Selective inhibitors of the osteoclast vacuolar proton ATPase as novel bone antiresorptive agents,” DDT, 4: 163-172 (1999)), which is hereby incorporated by reference in its entirety.
  • HMG-CoA reductase inhibitors refers to inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase.
  • Compounds which have inhibitory activity for HMG-CoA reductase can be readily identified by using assays well-known in the art. For example, see the assays described or cited in U.S. Pat. No. 4,231,938 at col. 6, and WO 84/02131 at pp. 30-33.
  • the terms “HMG-CoA reductase inhibitor” and “inhibitor of HMG-CoA reductase” have the same meaning when used herein.
  • HMG-CoA reductase inhibitors examples include but are not limited to lovastatin (MEVACOR®; see U.S. Pat. Nos. 4,231,938, 4,294,926 and 4,319,039), simvastatin (ZOCOR®; see U.S. Pat. Nos. 4,444,784, 4,820,850 and 4,916,239), pravastatin (PRAVACHOL®; see U.S. Pat. Nos. 4,346,227, 4,537,859, 4,410,629, 5,030,447 and 5,180,589), fluvastatin (LESCOL®; see U.S. Pat. Nos.
  • HMG-CoA reductase inhibitor as used herein includes all pharmaceutically acceptable lactone and open-acid forms (i.e., where the lactone ring is opened to form the free acid) as well as salt and ester forms of compounds which have HMG-CoA reductase inhibitory activity, and therefor the use of such salts, esters, open-acid and lactone forms is included within the scope of this invention.
  • An illustration of the lactone portion and its corresponding open-acid form is shown below as structures I and II.
  • HMG-CoA reductase inhibitors where an open-acid form can exist
  • salt and ester forms may preferably be formed from the open-acid, and all such forms are included within the meaning of the term “HMG-CoA reductase inhibitor” as used herein.
  • the HMG-CoA reductase inhibitor is selected from lovastatin and simvastatin, and most preferably simvastatin.
  • the term “pharmaceutically acceptable salts” with respect to the HMG-CoA reductase inhibitor shall mean non-toxic salts of the compounds employed in this invention which are generally prepared by reacting the free acid with a suitable organic or inorganic base, particularly those formed from cations such as sodium, potassium, aluminum, calcium, lithium, magnesium, zinc and tetramethylammonium, as well as those salts formed from amines such as ammonia, ethylenediamine, N-methylglucamine, lysine, arginine, ornithine, choline, N,N′-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, 1-p-chlorobenzyl-2-pyrrolidine-1′-yl-methylbenz-imidazole, diethylamine, piperazine, and tris(hydroxymethyl) aminomethane.
  • a suitable organic or inorganic base particularly those formed from cations such as
  • salt forms of HMG-CoA reductase inhibitors may include, but are not limited to, acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynapthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylsulfate, mucate, napsylate, nitrate, oleate, oxalate, pamao
  • Ester derivatives of the described HMG-CoA reductase inhibitor compounds may act as prodrugs which, when absorbed into the bloodstream of a warm-blooded animal, may cleave in such a manner as to release the drug form and permit the drug to afford improved therapeutic efficacy.
  • integrin receptor antagonists refers to compounds which selectively antagonize, inhibit or counteract binding of a physiological ligand to the ⁇ v ⁇ 3 integrin, to compounds which selectively antagonize, inhibit or counteract binding of a physiological ligand to the ⁇ v ⁇ 5 integrin, to compounds which antagonize, inhibit or counteract binding of a physiological ligand to both the ⁇ v ⁇ 3 integrin and the ⁇ v ⁇ 5 integrin, and to compounds which antagonize, inhibit or counteract the activity of the particular integrin(s) expressed on capillary endothelial cells.
  • the term also refers to antagonists of the ⁇ v ⁇ 6 , ⁇ v ⁇ 8 , ⁇ 1 ⁇ 1 , ⁇ 2 ⁇ 1 , ⁇ 5 ⁇ 1 , ⁇ 6 ⁇ 1 and ⁇ 6 ⁇ 4 integrins.
  • the term also refers to antagonists of any combination of ⁇ v ⁇ 3 , ⁇ v ⁇ 5 , ⁇ v ⁇ 6 , ⁇ v ⁇ 8 , ⁇ 1 ⁇ 1 , ⁇ 2 ⁇ 1 , ⁇ 5 ⁇ 1 , ⁇ 6 ⁇ 1 and ⁇ 6 ⁇ 4 integrins. H.N.
  • the ⁇ and ⁇ integrin subunits interact non-covalently and bind extracellular matrix ligands in a divalent cation-dependent manner.
  • the most abundant integrin on osteoclasts is ⁇ v ⁇ 3 (>10 7 /osteoclast), which appears to play a rate-limiting role in cytoskeletal organization important for cell migration and polarization.
  • the ⁇ v ⁇ 3 antagonizing effect is selected from inhibition of bone resorption, inhibition of restenosis, inhibition of macular degeneration, inhibition of arthritis, and inhibition of cancer and metastatic growth.
  • An osteoblast anabolic agent refers to agents that build bone, such as PTH.
  • PTH parathyroid hormone
  • the intermittent administration of parathyroid hormone (PTH) or its amino-terminal fragments and analogues have been shown to prevent, arrest, partially reverse bone loss and stimulate bone formation in animals and humans.
  • PTH parathyroid hormone
  • Studies have demonstrated the clinical benefits of parathyroid hormone in stimulating bone formation and thereby increasing bone mass and strength. Results were reported by R M Neer et al., in New Eng J Med 344 1434-1441 (2001).
  • parathyroid hormone-related protein fragments or analogues such as PTHrP-(1-36) have demonstrated potent anticalciuric effects [see M. A. Syed et al., “Parathyroid hormone-related protein-(1-36) stimulates renal tubular calcium reabsorption in normal human volunteers: implications for the pathogenesis of humoral hypercalcemia of malignancy,” JCEM 86: 1525-1531 (2001)] and may also have potential as anabolic agents for treating osteoporosis.
  • administration means introducing the compound or a prodrug of the compound into the system of the animal in need of treatment.
  • a compound of the invention or prodrug thereof is provided in combination with one or more other active agents (e.g., a cytotoxic agent, etc.)
  • administration and its variants are each understood to include concurrent and sequential introduction of the compound or prodrug thereof and other agents.
  • the present invention includes within its scope prodrugs of the compounds of this invention. In general, such prodrugs will be functional derivatives of the compounds of this invention which are readily convertible in vivo into the required compound.
  • the term “administering” shall encompass the treatment of the various conditions described with the compound specifically disclosed or with a compound which may not be specifically disclosed, but which converts to the specified compound in vivo after administration to the patient.
  • Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in “Design of Prodrugs,” ed. H. Bundgaard, Elsevier, 1985, which is incorporated by reference herein in its entirety. Metabolites of these compounds include active species produced upon introduction of compounds of this invention into the biological milieu.
  • composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
  • terapéuticaally effective amount means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.
  • treating includes: preventing the disease, i.e. causing the clinical symptoms of the disease not to develop in a mammal that may be exposed to or predisposed to the disease but does not yet experience or display symptoms of the disease; inhibiting the disease, i.e., arresting or reducing the development of the disease or its clinical symptoms; or relieving the disease, i.e., causing regression of the disease or its clinical symptoms.
  • bone resorption refers to the process by which osteoclasts degrade bone.
  • the present invention also encompasses a pharmaceutical composition useful in the treatment of osteoporosis or other bone. disorders, comprising the administration of a therapeutically effective amount of the..compounds of this invention, with or without pharmaceutically acceptable carriers or diluents.
  • Suitable compositions of this invention include aqueous solutions comprising compounds of this invention and pharmacologically acceptable carriers, e.g., saline, at a pH level, e.g., 7.4. The solutions may be introduced into a patient's bloodstream by local bolus injection.
  • the daily dosage will normally be determined by the prescribing physician with the dosage generally varying according to the age, weight, and response of the individual patient, as well as the severity of the patient's symptoms.
  • a suitable amount of compound is administered to a mammal undergoing treatment for a cathepsin dependent condition.
  • Oral dosages of the present invention when used for the indicated effects, will range between about 0.01 mg per kg of body weight per day (mg/kg/day) to about 100 mg/kg/day, preferably 0.01 to 10 mg/kg/day, and most preferably 0.1 to 5.0 mg/kg/day.
  • the compositions are preferably provided in the form of tablets containing 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100 and 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated.
  • a medicament typically contains from about 0.01 mg to about 500 mg of the active ingredient, preferably, from about 1 mg to about 100 mg of active ingredient.
  • the most preferred doses will range from about 0.1 to about 10 mg/kg/minute during a constant rate infusion.
  • compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily.
  • preferred compounds for the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using those forms of transdermal skin patches well known to those of ordinary skill in the art.
  • the dosage administration will, of course, be continuous rather than intermittant throughout the dosage regimen.
  • the compounds of the present invention can be used in combination with other agents useful for treating cathepsin-mediated conditions.
  • the individual components of such combinations can be administered separately at different times during the course of therapy or concurrently in divided or single combination forms.
  • the instant invention is therefore to be understood as embracing all such regimes of simultaneous or alternating treatment and the term “administering” is to be interpreted accordingly.
  • the scope of combinations of the compounds of this invention with other agents useful for treating cathepsin-mediated conditions includes in principle any combination with any pharmaceutical composition useful for treating disorders related to estrogen functioning.
  • the scope of the invetion therefore encompasses the use of the instantly claimed compounds in combination with a second agent selected from: an organic bisphosphonate; an estrogen receptor modulator; an androgen receptor modulator; an inhibitor of osteoclast proton ATPase; an inhibitor of HMG-CoA reductase; an integrin receptor antagonist; an osteoblast anabolic agent, such as PTH; and the pharmaceutically acceptable salts and mixtures thereof.
  • a second agent selected from: an organic bisphosphonate; an estrogen receptor modulator; an androgen receptor modulator; an inhibitor of osteoclast proton ATPase; an inhibitor of HMG-CoA reductase; an integrin receptor antagonist; an osteoblast anabolic agent, such as PTH; and the pharmaceutically acceptable salts and mixtures thereof.
  • the compounds of the present invention may have asymmetric centers, chiral axes, and chiral planes (as described in: E. L. Eliel and S. H. Wilen, Stereochemistry of Carbon Compounds, John Wiley & Sons, New York, 1994, pages 1119-1190), and occur as racemates, racemic mixtures, and as individual diastereomers, with all possible isomers and mixtures thereof, including optical isomers, being included in the present invention.
  • the compounds disclosed herein may exist as tautomers and both tautomeric forms are intended to be encompassed by the scope of the invention, even though only one tautomeric structure is depicted. For example, any claim to compound A below is understood to include tautomeric structure B, and vice versa, as well as mixtures thereof.
  • any variable e.g. R1, R2, Ra etc.
  • its definition on each occurrence is independent at every other occurrence.
  • combinations of substituents and variables are permissible only if such combinations result in stable compounds.
  • Lines drawn into the ring systems from substituents indicate that the indicated bond may be attached to any of the substitutable ring carbon atoms. If the ring system is polycyclic, it is intended that the bond be attached to any of the suitable carbon atoms on the proximal ring only.
  • substituents and substitution patterns on the compounds of the instant invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques known in the art, as well as those methods set forth below, from readily available starting materials. If a substituent is itself substituted with more than one group, it is understood that these multiple groups may be on the same carbon or on different carbons, so long as a stable structure results.
  • the phrase “optionally substituted with one or more substituents” should be taken to be equivalent to the phrase “optionally substituted with at least one substituent” and in such cases the preferred embodiment will have from zero to three substituents.
  • alkyl is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having one to ten carbon atoms unless otherwise specified.
  • C 1 -C 10 as in “C 1 -C 10 alkyl” is defined to include groups having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbons in a linear, branched, or cyclic arrangement.
  • C 1 -C 10 alkyl specifically includes methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, and so on.
  • Alkoxy or “alkyloxy” represents an alkyl group as defined above, unless otherwise indicated, wherein said alkyl group is attached through an oxygen bridge.
  • cycloalkyl or “carbocycle” shall mean cyclic rings of alkanes of three to eight total carbon atoms, unless otherwise indicated, or any number within this range (i.e., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl).
  • alkenyl refers to a non-aromatic hydrocarbon radical, straight or branched, containing from 2 to 10 carbon atoms and at least 1 carbon to carbon double bond. Preferably 1 carbon to carbon double bond is present, and up to 4 non-aromatic carbon-carbon double bonds may be present.
  • C 2 -C 6 alkenyl means an alkenyl radical having from 2 to 6 carbon atoms.
  • Alkenyl groups include ethenyl propenyl, butenyl and cyclohexenyl. As described above with respect to alkyl, the straight, branched or cyclic portion of the alkenyl group may contain double bonds and may be substituted if a substituted alkenyl group is indicated.
  • cycloalkenyl shall mean cyclic rings of 3 to 10 carbon atoms, unless otherwise specified, containing at least 1 carbon to carbon double bond (i.e., cyclopropenyl, cyclobutenyl, cyclopenentyl, cyclohexenyl, cycloheptenyl or cycloocentyl).
  • alkynyl refers to a hydrocarbon radical straight or branched, containing from 2 to 10 carbon atoms, unless otherwise specified, containing at least 1 carbon to carbon triple bond. Up to 3 carbon-carbon triple bonds may be present.
  • C 2 -C 6 alkynyl means an alkynyl radical having from 2 to 6 carbon atoms.
  • Alkynyl groups include ethynyl, propynyl and butynyl. As described above with respect to alkyl, the straight, branched or cyclic portion of the alkynyl group may contain triple bonds and may be substituted if a substituted alkynyl group is indicated.
  • substituents may be defined with a range of carbons that includes zero, such as (C 0 -C 6 )alkylene-aryl. If aryl is taken to be phenyl, this definition would include phenyl itself as well as —CH 2 Ph, —CH 2 CH 2 Ph, CH(CH 3 ) CH 2 CH(CH 3 )Ph, and so on.
  • aryl is intended to mean any stable monocyclic or bicyclic carbon ring of up to 12 atoms in each ring, wherein at least one ring is aromatic.
  • aryl elements include phenyl, naphthyl, tetrahydronaphthyl, indanyl, biphenyl, phenanthryl, anthryl or acenaphthyl.
  • the aryl substituent is bicyclic and one ring is non-aromatic, it is understood that attachment is via the aromatic ring.
  • heteroaryl represents a stable monocyclic, bicyclic or tricyclic ring of up to 10 atoms in each ring, wherein at least one ring is aromatic and contains from 1 to 4 heteroatoms selected from the group consisting of O, N and S.
  • Heteroaryl groups within the scope of this definition include but are not limited to: benzoimidazolyl, benzofuranyl, benzofurazanyl, benzopyrazolyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, cinnolinyl, furanyl, indolinyl, indolyl, indolazinyl, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthpyridinyl, oxadiazolyl, oxazolyl, oxazoline, isoxazoline, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridopyridinyl, pyridyl, pyrimidinyl, pyrrolyl, quinazoliny
  • heteroaryl substituent is bicyclic and one ring is non-aromatic or contains no heteroatoms, it is understood that attachment is via the aromatic ring or via the heteroatom containing ring, respectively. If the heteroaryl contains nitrogen atoms, it is understood that the corresponding N-oxides thereof are also encompassed by this definition.
  • halo or halogen as used herein is intended to include chloro, fluoro, bromo and iodo.
  • keto means carbonyl (C ⁇ O).
  • alkoxy as used herein means an alkyl portion, where alkyl is as defined above, connected to the remainder of the molecule via an oxygen atom. Examples of alkoxy include methoxy, ethoxy and the like.
  • haloalkyl means an alkyl radical as defined above, unless otherwise specified, that is substituted with one to five, preferably one to three halogen. Representative examples include, but are not limited to trifluoromethyl, dichloroethyl, and the like.
  • haloalkoxy represents a radical —OR where R is alkyl as defined above that is substituted with one to five, preferably one to three halogen. Representative examples include, but are not limited to trifluoromethyloxy, dichloroethyloxy, and the like.
  • arylalkyl includes an alkyl portion where alkyl is as defined above and to include an aryl portion where aryl is as defined above.
  • arylalkyl include, but are not limited to, benzyl, fluorobenzyl, chlorobenzyl, phenylethyl, phenylpropyl, fluorophenylethyl, and chlorophenylethyl.
  • alkylaryl include, but are not limited to, toluyl, ethylphenyl, and propylphenyl.
  • heteroarylalkyl shall refer to a system that includes a heteroaryl portion, where heteroaryl is as defined above, and contains an alkyl portion.
  • heteroarylalkyl include, but are not limited to, thienylmethyl, thienylethyl, thienylpropyl, pyridylmethyl, pyridylethyl and imidazoylmethyl.
  • cycloalkylalkyl includes an alkyl portion where alkyl is as defined above and also includes an cycloalkyl portion where cycloalkyl is as defined above.
  • examples of cycloalkylalkyl include, but are not limited to, cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl, cyclopropylethyl, and the like.
  • hydroxyalkyl means a linear monovalent hydrocarbon raidcal of one to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbons substituted with one or two hydroxy groups, provided that if two hydroxy groups are present they are not both on the same carbon atom.
  • Representative examples include, but are not limited to, hydroxymethyl, 2-hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, and the like.
  • heterocycle or “heterocyclyl” as used herein is intended to mean a 5- to 10-membered nonaromatic ring, unless otherwise specified, containing from 1 to 4 heteroatoms selected from the group consisting of O, N, S, SO, or SO 2 and includes bicyclic groups.
  • “Heterocyclyl” therefore includes, but is not limited to the following: piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, tetrahydropyranyl, dihydropiperidinyl, tetrahydrothiophenyl and the like. If the heterocycle contains a nitrogen, it is understood that the corresponding N-oxides thereof are also emcompassed by this definition.
  • the present invention also includes N-oxide derivatives and protected derivatives of compounds of Formula I.
  • compounds of Formula I when compounds of Formula I contain an oxidizable nitrogen atom, the nitrogen atom can beconverted to an N-oxide by methods well known in the art.
  • compounds of Formula I when compounds of Formula I contain groups such as hydroxy, carboxy, thiol or any group containing a nitrogen atom(s), these groups can be protected with a suitable protecting groups.
  • a comprehensive list of suitable protective groups can be found in T. W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, Inc. 1981, the disclosure of which is incorporated herein by reference in its entirety.
  • the protected derivatives of compounds of Formula I can be prepared by methods well known in the art.
  • alkyl or aryl or either of their prefix roots appear in a name of a substituent (e.g., aryl C 0-8 alkyl) it shall be interpreted as including those limitations given above for “alkyl” and “aryl.” Designated numbers of carbon atoms (e.g., C 1-10 ) shall refer independently to the number of carbon atoms in an alkyl or cyclic alkyl moiety or to the alkyl portion of a larger substituent in which alkyl appears as its prefix root.
  • the pharmaceutically acceptable salts of the compounds of this invention include the conventional non-toxic salts of the compounds of this invention as formed inorganic or organic acids.
  • conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like, as well as salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxy-benzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, trifluoroacetic and the like.
  • the preparation of the pharmaceutically acceptable salts described above and other typical pharmaceutically acceptable salts is more fully described by Berg et al., “Pharmaceutical Salts,” J. Pharm. Sci., 1977:66:1-19, hereby incorporated by reference.
  • the pharmaceutically acceptable salts of the compounds of this invention can be synthesized from the compounds of this invention which contain a basic or acidic moiety by conventional chemical methods. Generally, the salts of the basic compounds are prepared either by ion exchange chromatography or by reacting the free base with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid in a suitable solvent or various combinations of solvents. Similarly, the salts of the acidic compounds are formed by reactions with the appropriate inorganic or organic base.
  • CCl 4 carbon tetrachloride
  • DIPEA diisopropylethylamine
  • EDCl 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
  • HATU o-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate
  • K 2 CO 3 potassium carbonate
  • KHMDS potassium hexamethyldisilazane
  • MgSO 4 magnesium sulfate
  • NaCNBH 3 sodium cyanoborohydride
  • NaHCO 3 sodium hydrogencarbonate
  • Na 2 SO 4 sodium sulfate
  • NBS N-bromosuccinimide
  • PPTS pyridinium p-toluenesulfonate
  • TMSCl chlorotrimethylsilane
  • novel compounds of the present invention can be prepared according to the following general procedures using appropriate materials and are further exemplified by the following specific examples.
  • the compounds illustrated in the examples are not, however, to be construed as forming the only genus that is considered as the invention.
  • the following examples further illustrate details for the preparation of the compounds of the present invention. Those skilled in the art will readily understand that known variations of the conditions and processes of the following preparative procedures can be used to prepare these compounds. All temperatures are degrees Celsius unless otherwise noted.
  • Compounds of the current invention may also be prepared according to Scheme 4.
  • An appropriately substituted acetate may be enolized with a suitable base (including, but not limited to LDA, KHMDS, NaH or nBuLi) and treated with paraformaldehyde to generate the diol.
  • This diol may be converted to the difluoride using a fluorinating reagent such as DAST. Hydrolysis of the ester followed by Curtius rearrangement will then provide the amine.
  • This amine can displace an appropriately substituted alpha-bromo ester to provide the alpha-amino ester. This may be converted into compounds of the current invention by the method described in Scheme 1.
  • Compounds of the current invention may also be prepared according to Scheme 5, as indicated below.
  • a hemiacetal may be condensed with an amino alcohol in which the alcohol moiety is protected with a suitable protecting group.
  • Treatment of the resulting imine with a Grignard reagent or organolithium reagent will provide the appropriate alkylated amino alcohol.
  • the alcohol protecting group can then be removed and the alcohol can be converted into compounds of the current invention either by the method described in Scheme 2 or by first conducting the Suzuki reaction, followed by oxidizing the alcohol with H 5 IO 6 /CrO 3 and then peptide coupling.
  • the 4-fluoroleucinol can also be synthesized according to Scheme 8. 4,5-Dehydroleucine is converted to (4S)-4-(2-methylprop-2-enyl)-1,3-oxazolidin-2-one as described in the scheme below. This intermediate is then treated with a hydrofluorination reagent such as HF-pyridine to give (4S)-4-(2-fluoro-2-methylpropyl)-1,3-oxazolidin-2-one. Basic hydrolysis (i.e. Ba(OH) 2 or NaOH) then affords (2S)-2-amnino-4-fluoro-4-methylpentan-1-ol.
  • a hydrofluorination reagent such as HF-pyridine
  • the amino alcohols used for the present invention can also be synthesized according to Scheme 10.
  • a protected amino acid is reduced with a reducing agent such as NaBH 4 with or without an additive such as LiCl, in a solvent such as EtOH or a mixed solvent system such as EtOH and THF.
  • the amino protecting group is then removed with the appropriate method according to the nature of the protecting group.
  • the isolated 5,5,5-trifluoro-L-leucine is then protected with a protecting group such as benzyl carbamate and the carboxylic acid group is esterified.
  • a protecting group such as benzyl carbamate
  • carboxylic acid group is esterified.
  • the two diastereomers at the 4-position are then separated by flash column chromatography.
  • One of the enantiomers, the (2S,4S) protected amino acid is then converted to the amino alcohol as described in scheme 10.
  • the alkylated aminoalcohol is then converted into compounds of the current invention either by the method described in Scheme 2 or by first conducting the Suzuki reaction with the boronic ester of the formula R 7 —B(OH) 2 , then oxidizing the alcohol with a suitable oxidizing agent such as H 5 IO 6 /CrO 3 to give the acid and finally treating the acid with an aminoacetonitrile under peptide coupling conditions as described previously.
  • a suitable oxidizing agent such as H 5 IO 6 /CrO 3
  • Step 4 N 2 - ⁇ (4-bromophenyl)[4-(methylsulfonyl)phenyl]methyl ⁇ -N 1 -(cyanomethyl)-L-leucinamide
  • Step 5 N 1 -(cyanomethyl)-N 2 - ⁇ [4-(methylsulfonyl)phenyl][4′-(methylthio)-1,1′-biphenyl-4-yl]methyl ⁇ -L-leucinamide
  • Step 6 N 1 -(Cyanomethyl)-N 2 - ⁇ [4′-(methylsulfonyl)-1,1′-biphenyl-4-yl][4-(methylsulfonyl)phenyl]methyl ⁇ -L-Leucinamide
  • Step 2 Preparation of (2S)-1- ⁇ [tert-butyl(dimethyl)silyl]oxy ⁇ -4-methyl-N-[(1E)-2,2,2-trifluoroethylidene]pentan-2-amine
  • Step 3 Preparation of (2S)-2- ⁇ [(1S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl]amino ⁇ -4-methylpentan-1-ol
  • n-BuLi 2.5 M in hexanes, 42 mL was added to a ⁇ 70° C.
  • THF 400 mL solution of 1,4-dibromobenzene (25.8 g) and the mixture was stirred for 25 minutes.
  • Step 4 Preparation of (2S)-4-methyl-2-( ⁇ (1S)-2,2,2-trifluoro-1-[4′-(methylthio)-1,1′-biphenyl-4-yl]ethyl ⁇ amino)pentan-1-ol
  • the ethyl acetate layer was separated and the aqueous further extracted with ethyl acetate (200 mL).
  • the combined ethyl acetate extracts were washed with 0.5 N NaOH (2 ⁇ 200 mL), with aqueous NH 4 Cl, brine and dried with magnesium sulfate. Removal of the solvent left a residue that was purified by chromatography on SiO 2 using a gradient of ethyl acetate and hexanes (1:4 to 1:3) and again with acetone and toluene (1:10). The residue was dissolve in hot hexanes (200 mL) and the solution was allowed to cool to 0° C. under stirring. The obtained solid was filtered and dried to yield the title compound.
  • Step 5 Preparation of (2S)-4-methyl-2-( ⁇ (1S)-2,2,2-trifluoro-1-[4′-(methylsulfonyl)-1,1′-biphenyl-4-yl]ethyl ⁇ amino)pentan-1-ol
  • Step 6 Preparation of N- ⁇ (1S)-2,2,2-trifluoro-1-[4′-(methylsulfonyl)-1,1′-biphenyl-4-yl]ethyl ⁇ -L-leucine
  • Step 7 Preparation of N 1 (cyanomethyl)-N 2 ⁇ (1S)-2,2,2-trifluoro-1-[4′-(methylsulfonyl)-1,1′-biphenyl-4-yl]ethyl ⁇ -L-leucinamide
  • Step 1 Preparation of N 2 [(1S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl]-N 1 (cyanomethyl)-L-leucinamide
  • Step 2 Preparation of N 1 -(cyanomethyl)-N 2 ⁇ (1S)-2,2,2-trifluoro-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethyl ⁇ -L-leucinamide
  • the mixture was cooled to room temperature, diluted with ethylacetate and hexanes (1:1, 300 mL) and poured over water (2 L) and ice (500 g). The organic layer was separated and the aqueous layer further extracted with ethyl acetate and hexanes (1:1, 3 ⁇ 200 mL). The combined extracts were washed with brine and dried with magnesium sulfate. Removal of the solvent left a residue that was purified by chromatography on SiO 2 using ethyl acetate and hexanes (1:2) to yield the boronate.
  • Step 3 Preparation of N 2 ⁇ (1S)-1-[4′-(aminosulfonyl)-1,1′-biphenyl-4-yl]-2,2,2-trifluoroethyl ⁇ -N 1 (cyanomethyl)-L-leucinamide
  • the ethyl acetate layer was separated and the aqueous further extracted with ethyl acetate (100 mL).
  • the combined ethyl acetate extracts were washed with dilute aqueous NaHCO 3 , brine and dried with magnesium sulfate. Removal of the solvent left a residue that was purified by chromatography on SiO 2 using a gradient of ethyl acetate, hexanes and dichloromethane (2:3:0.1 to 1:1:0.1).
  • the product was then stirred in diethyl ether for 16 hours, filtered and dried to yield the title compound.
  • the mixture was kept at room temperature for 48 hours and then poured into dilute aqueous ammonium cholride and diethyl ether.
  • the ether layer was separated and the aqueous further extracted with diethylether.
  • the combined ether extracts were washed with brine, dried with magnesium sulfate and the solvent was removed in vacuo.
  • the residue was purified in SiO 2 using ethyl acetate and hexanes (1:1) as eluant, followed by a swish in diethyl ether to yield the title compound.
  • Step 1 Preparation of (4S)-4-isobutyl-2-(pentafluoroethyl)-1,3-oxazolidine
  • Pentafluoropropanal methyl hemiacetal (14.9 g, 82.8 mmol) and L-leucinol (9.7 g, 82.8 mmol) were dissolved in 100 mL of benzene and heated to reflux overnight in a flask equipped with a Dean-Stark tube. The resulting solution was cooled and concentrated to provide the title compound as an oil which was used directly in the following step.
  • Step 2 Preparation of (2S)-2- ⁇ [(1S)-1-(4-bromophenyl)-2,2,3,3,3-pentafluoropropyl]amino ⁇ -4-methylpentan-1-ol
  • Step 3 Preparation of N 2 -[(1S)-1-(4-bromophenyl)-2,2,3,3,3-pentafluoropropyl]-N 1 -(cyanomethyl)-L-leucinamide
  • Step 4 Preparation of N 1 -(cyanomethyl)-N 2 -[(1S)-2,2,3,3,3-pentafluoro-1-(4-pyridin-4-ylphenyl)propyl]-L-leucinamide
  • Step 1 Preparation of (2S)-1- ⁇ [tert-butyl(dimethyl)silyl]oxy ⁇ -4-methylpentan-2-amine
  • Step 2 Preparation of (2S)-1- ⁇ [tert-butyl(dimethyl)silyl]oxy ⁇ -N-[(1E)-2,2-difluoroethylidene-]-4-methylpentan-2-amine
  • Step 3 Preparation of (2S)-2- ⁇ [(1S)-1-(4-bromophenyl)-2,2-difluoroethyl]amino 1-4-methylpentan-1-ol
  • n-BuLi 2.5 M in hexanes, 1.43 mL was added to a ⁇ 70° C.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Quinoline Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
US10/377,377 2002-03-05 2003-02-28 Cathepsin cysteine protease inhibitors Abandoned US20030232863A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/377,377 US20030232863A1 (en) 2002-03-05 2003-02-28 Cathepsin cysteine protease inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36181802P 2002-03-05 2002-03-05
US40870402P 2002-09-06 2002-09-06
US10/377,377 US20030232863A1 (en) 2002-03-05 2003-02-28 Cathepsin cysteine protease inhibitors

Publications (1)

Publication Number Publication Date
US20030232863A1 true US20030232863A1 (en) 2003-12-18

Family

ID=27807943

Family Applications (6)

Application Number Title Priority Date Filing Date
US10/377,377 Abandoned US20030232863A1 (en) 2002-03-05 2003-02-28 Cathepsin cysteine protease inhibitors
US10/505,796 Active 2024-11-20 US7375134B2 (en) 2002-03-05 2003-02-28 Cathepsin cysteine protease inhibitors
US12/082,104 Active 2024-09-24 US7973037B2 (en) 2002-03-05 2008-04-08 Cathepsin cysteine protease inhibitors
US13/115,462 Expired - Lifetime US8318748B2 (en) 2002-03-05 2011-05-25 Cathepsin cysteine protease inhibitors
US13/649,670 Expired - Lifetime US8772336B2 (en) 2002-03-05 2012-10-11 Cathepsin cysteine protease inhibitors
US14/282,395 Abandoned US20140256743A1 (en) 2002-03-05 2014-05-20 Cathepsin cysteine protease inhibitors

Family Applications After (5)

Application Number Title Priority Date Filing Date
US10/505,796 Active 2024-11-20 US7375134B2 (en) 2002-03-05 2003-02-28 Cathepsin cysteine protease inhibitors
US12/082,104 Active 2024-09-24 US7973037B2 (en) 2002-03-05 2008-04-08 Cathepsin cysteine protease inhibitors
US13/115,462 Expired - Lifetime US8318748B2 (en) 2002-03-05 2011-05-25 Cathepsin cysteine protease inhibitors
US13/649,670 Expired - Lifetime US8772336B2 (en) 2002-03-05 2012-10-11 Cathepsin cysteine protease inhibitors
US14/282,395 Abandoned US20140256743A1 (en) 2002-03-05 2014-05-20 Cathepsin cysteine protease inhibitors

Country Status (28)

Country Link
US (6) US20030232863A1 (fr)
EP (1) EP1482924B1 (fr)
JP (2) JP4201716B2 (fr)
KR (1) KR100975784B1 (fr)
CN (1) CN100430052C (fr)
AT (1) ATE395911T1 (fr)
AU (1) AU2003219953B8 (fr)
BR (1) BRPI0308208B8 (fr)
CA (1) CA2477657C (fr)
CL (1) CL2003001743A1 (fr)
CY (1) CY1111130T1 (fr)
DE (1) DE60321141D1 (fr)
DK (1) DK1482924T3 (fr)
EC (1) ECSP045261A (fr)
ES (1) ES2305452T3 (fr)
HK (1) HK1080375A1 (fr)
HR (1) HRP20040800B1 (fr)
IL (2) IL163748A0 (fr)
IS (1) IS2549B (fr)
MA (1) MA27295A1 (fr)
MX (1) MXPA04008621A (fr)
NO (1) NO335099B1 (fr)
NZ (1) NZ534583A (fr)
PL (1) PL215865B1 (fr)
PT (1) PT1482924E (fr)
RU (1) RU2312861C2 (fr)
SI (1) SI1482924T1 (fr)
WO (1) WO2003075836A2 (fr)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005019161A1 (fr) * 2003-08-21 2005-03-03 Merck Frosst Canada Ltd. Inhibiteurs de cathepsine et de cysteine protease
WO2006017455A2 (fr) 2004-08-04 2006-02-16 Merck & Co., Inc. Procédé diastéréosélectif d’amination réductrice
US20060069122A1 (en) * 2004-09-29 2006-03-30 Anormed Inc. Chemokine-binding heterocyclic compound salts, and methods of use thereof
US20060111440A1 (en) * 2004-11-23 2006-05-25 Gauthier Jacques Y Cathepsin cysteine protease inhibitors
US20080214676A1 (en) * 2006-10-04 2008-09-04 Virobay, Inc. Di-fluoro containing compounds as cysteine protease inhibitors
US20080293819A1 (en) * 2006-10-04 2008-11-27 Virobay, Inc. Di-fluoro containing compounds as cysteine protease inhibitors
US7482448B2 (en) 2003-10-24 2009-01-27 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
US20090264479A1 (en) * 2005-07-26 2009-10-22 Cameron Black Papain Family Cysteine Protease Inhibitors for the Treatment of Parasitic Diseases
US20090291945A1 (en) * 2008-04-09 2009-11-26 Teijin Pharma Limited Cysteine protease inhibitors
WO2009140105A3 (fr) * 2008-05-14 2010-01-07 Merck & Co., Inc. Préparations pour inhibiteurs de la cathepsine k
US20100130782A1 (en) * 2007-04-02 2010-05-27 Merck Frosst Canada Ltd. Amidation process for the preparation of cathepsin k inhibitors
US20100305056A1 (en) * 2007-11-29 2010-12-02 Merck Frosst Canada Ltd. Cysteine protease inhibitors for the treatment of parasitic disease
US20110046406A1 (en) * 2009-08-19 2011-02-24 Virobay, Inc. Process for the preparation of (s)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof
US10494364B2 (en) 2015-08-29 2019-12-03 Sunshin Lake Pharma Co., Ltd Cathepsin K inhibitors and application thereof
US11299478B2 (en) 2018-03-28 2022-04-12 Hanlim Pharmaceutical Co., Ltd. 2-cyanopyrimidin-4-yl carbamate or urea derivative or salt thereof, and pharmaceutical composition including same
RU2772276C2 (ru) * 2017-01-24 2022-05-18 Астеллас Фарма Инк. Фенилдифторметилзамещенное соединение пролинамида

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9937531B2 (en) 2009-03-10 2018-04-10 Bookit Oy Ajanvarauspalvelu Method and system for delivery of goods
PT1469833T (pt) 2002-02-01 2021-07-13 Bend Res Inc Método para produzir dispersões de fármaco amorfo sólido seco por pulverização homogéneas utilizando aparelho de secagem por pulverização modificado
AU2003219953B8 (en) 2002-03-05 2008-09-25 Axys Pharmaceuticals, Inc. Cathepsin cysteine protease inhibitors
WO2003077948A1 (fr) * 2002-03-19 2003-09-25 Kowa Co., Ltd. Myelome : medicaments preventifs/curatifs et methode de diagnostic
DE602004023838D1 (de) * 2003-04-24 2009-12-10 Merck & Co Inc Hemmer der akt aktivität
CN1842515A (zh) * 2003-08-27 2006-10-04 默克弗罗斯特加拿大有限公司 组织蛋白酶抑制剂
KR20060079143A (ko) * 2003-09-18 2006-07-05 액시스 파마슈티컬스 인코포레이티드 시스테인 프로테아제 억제제로서의 할로알킬 함유 화합물
EP1694647B1 (fr) * 2003-12-12 2016-11-09 Merck Canada Inc. Inhibiteurs des protéases à cystéine du type cathepsine
AU2005203820A1 (en) * 2004-01-08 2005-07-21 Merck Frosst Canada Ltd Cathepsin cysteine protease inhibitors
US7429674B2 (en) 2004-04-14 2008-09-30 Merck & Co. Inc.. Process for preparing fluoroleucine alkyl esters
AU2005287046A1 (en) * 2004-09-17 2006-03-30 Bayer Schering Pharma Aktiengesellschaft Processes and intermediates for preparing cysteine protease inhibitors
EP1817275A1 (fr) 2004-12-01 2007-08-15 Schering Aktiengesellschaft Composes contenant un haloalkyle, utilises comme inhibiteurs de cysteine proteases
EP1819667B1 (fr) 2004-12-02 2012-10-17 ViroBay, Inc. Composes de sulfonamide utilises comme inhibiteurs des cysteine proteases
EP1841419A4 (fr) * 2005-01-19 2009-02-25 Merck Frosst Canada Ltd Inhibiteurs de la cathepsine k et obesite
US20080125442A1 (en) * 2005-01-19 2008-05-29 Michael David Percival Cathepsin K Inhibitors and Atherosclerosis
WO2006093467A1 (fr) * 2005-03-02 2006-09-08 Agency For Science, Technology And Research Molecules organiques conjuguees destinees a des dispositifs electroniques moleculaires
WO2007046842A2 (fr) 2005-03-02 2007-04-26 Merck & Co., Inc. Composition destinee a l'inhibition de cathepsine k
KR101447897B1 (ko) 2005-03-21 2014-10-07 비로베이, 인코포레이티드 시스테인 단백질분해효소 억제제로서의 알파 케토아미드화합물
MX2007011739A (es) * 2005-03-22 2008-03-14 Celera Genomics Compuestos que contienen sulfonilo como inhibidores de cisteina proteasa.
EP1891003A4 (fr) 2005-06-02 2010-07-21 Merck Frosst Canada Ltd Derives de fluoroalkylamine utilises comme inhibiteurs de la cathepsine
CN101267813A (zh) 2005-07-19 2008-09-17 第一三共株式会社 取代丙酰胺衍生物和含有其的药物组合物
RU2478620C2 (ru) 2006-06-01 2013-04-10 Санофи-Авентис Спироциклические нитрилы в качестве ингибиторов протеазы
US7622593B2 (en) * 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
WO2008080969A1 (fr) * 2006-12-29 2008-07-10 Abbott Gmbh & Co. Kg Composés de type carboxamide et leur utilisation comme inhibiteurs des calpaïnes
US20090318560A1 (en) 2007-02-26 2009-12-24 Wayne Parent Formulations for cathepsin k inhibitors
KR20100023948A (ko) 2007-06-08 2010-03-04 닛뽕 케미파 가부시키가이샤 뇌동맥류의 치료 또는 예방약
WO2009054454A1 (fr) 2007-10-24 2009-04-30 National University Corporation Tokyo Medical And Dental University Régulateur pour la signalisation du récepteur toll-like, comportant un inhibiteur de la cathepsine comme principe actif
JPWO2009096198A1 (ja) * 2008-02-01 2011-05-26 一般社団法人ファルマＩｐ 新規ビアリール誘導体
BRPI0822420A2 (pt) * 2008-04-01 2014-10-07 Virobay Inc Composto, composição farmaceutica, e, métodos para tratar uma doença em uma animal e para tratar um paciente que passa por uma tarepia.
JP5518997B2 (ja) 2009-04-20 2014-06-11 エフ．ホフマン−ラ ロシュ アーゲー カテプシン阻害薬としてのプロリン誘導体
US9051304B2 (en) * 2009-12-22 2015-06-09 AbbVie Deutschland GmbH & Co. KG Carboxamide compounds and their use as calpain inhibitors V
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
EP2675440B1 (fr) * 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Inhibiteurs de cystéine protéases, les cathepsines
US20130331597A1 (en) * 2011-03-02 2013-12-12 Guy Humphrey Amidation process
WO2012151319A1 (fr) 2011-05-02 2012-11-08 Virobay, Inc. Inhibiteur de cathepsine pour le traitement du cancer des os et de la douleur provoquée par le cancer des os
RU2013155509A (ru) 2011-05-16 2015-06-27 Байер Интеллектуэль Проперти Гмбх Применение ингибирования катепсина к для лечения и/или профилактики легочной гипертензии и/или сердечной недостаточности
US10023862B2 (en) 2012-01-09 2018-07-17 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat beta-catenin-related diseases
EA036592B1 (ru) 2012-06-13 2020-11-26 Инсайт Холдингс Корпорейшн Замещенные трициклические соединения как ингибиторы fgfr
WO2014026125A1 (fr) 2012-08-10 2014-02-13 Incyte Corporation Dérivés de pyrazine en tant qu'inhibiteurs de fgfr
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
KR102279999B1 (ko) 2013-02-19 2021-07-22 노파르티스 아게 선택적 에스트로겐 수용체 분해제로서의 벤조티오펜 유도체 및 그의 조성물
RU2737434C2 (ru) 2013-03-13 2020-11-30 Форма Терапьютикс, Инк. Новые соединения и композиции для ингибирования fasn
WO2014172644A2 (fr) 2013-04-19 2014-10-23 Incyte Corporation Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr
WO2014184378A1 (fr) 2013-05-16 2014-11-20 Sandoz Ag Comprimé à charge médicamenteuse accrue d'odanacatib
EP2808012A1 (fr) 2013-05-29 2014-12-03 ratiopharm GmbH Procédé de production de forme posologique comportant de l'odanacatib
JP6336973B2 (ja) 2013-06-14 2018-06-06 生化学工業株式会社 α−オキソアシルアミノカプロラクタム誘導体
WO2014199645A1 (fr) 2013-06-14 2014-12-18 生化学工業株式会社 CORPS α-OXOACYL AMINO-CAPROLACTAM
WO2015006177A1 (fr) * 2013-07-11 2015-01-15 Merck Sharp & Dohme Corp. Formulations pour inhibiteurs de la cathepsine k avec de la vitamine d
AU2014332250B2 (en) * 2013-10-08 2018-07-19 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
WO2015092634A1 (fr) 2013-12-16 2015-06-25 Novartis Ag Composés et compositions de 1,2,3,4-tétrahydroisoquinoléine en tant qu'antagonistes et agents de dégradation sélectifs des récepteurs des œstrogènes
WO2015107494A1 (fr) 2014-01-17 2015-07-23 Novartis Ag Dérivés de 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine et compositions les contenant pour l'inhibition de l'activité de shp2
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
EP3094627B1 (fr) 2014-01-17 2018-08-22 Novartis AG Dérivés de 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine et compositions les contenant pour l'inhibition de l'activité de shp2
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CZ2014941A3 (cs) 2014-12-19 2016-06-29 Zentiva, K.S. Příprava vysoce čistého intermediátu pro syntézu Odanacatibu
ES2895769T3 (es) 2015-02-20 2022-02-22 Incyte Corp Heterociclos bicíclicos como inhibidores de FGFR
WO2016134294A1 (fr) 2015-02-20 2016-08-25 Incyte Corporation Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
JP6695353B2 (ja) 2015-03-25 2020-05-20 ノバルティス アーゲー Ｆｇｆｒ４阻害剤としてのホルミル化ｎ−複素環式誘導体
ES2824576T3 (es) 2015-06-19 2021-05-12 Novartis Ag Compuestos y composiciones para inhibir la actividad de SHP2
CN112625028A (zh) 2015-06-19 2021-04-09 诺华股份有限公司 用于抑制shp2活性的化合物和组合物
WO2016203404A1 (fr) 2015-06-19 2016-12-22 Novartis Ag Composés et compositions pour inhiber l'activité de shp2
EP3380455A1 (fr) * 2015-11-26 2018-10-03 H. Hoffnabb-La Roche Ag Inhibiteurs de trypanosomes
CN106866502B (zh) * 2015-12-10 2020-10-09 广东东阳光药业有限公司 组织蛋白酶k抑制剂及其用途
DK3452465T3 (da) 2016-05-04 2021-02-08 Genoscience Pharma Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme
ES2810852T3 (es) 2016-06-14 2021-03-09 Novartis Ag Compuestos y composiciones para inhibir la actividad de shp2
JP7001068B2 (ja) * 2017-01-24 2022-01-19 アステラス製薬株式会社 フェニルジフルオロメチル置換プロリンアミド化合物
KR101916396B1 (ko) 2017-02-20 2018-11-08 서울대학교 산학협력단 항암제 또는 항균제로 사용될 수 있는 단백질분해효소 저해제
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
TW201912639A (zh) 2017-09-11 2019-04-01 美商克魯松藥物公司 Ｓｈｐ２之八氫環戊烷并[c]吡咯別構抑制劑
NL2020021B1 (en) * 2017-12-05 2019-06-13 Academisch Ziekenhuis Leiden Cathepsin inhibitors
WO2019112426A1 (fr) * 2017-12-05 2019-06-13 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) Inhibiteurs de la cathepsine
CA3099287A1 (fr) 2018-05-04 2019-11-07 Incyte Corporation Formes solides d'un inhibiteur de fgfr et leurs procedes de preparation
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
MX2021003158A (es) 2018-09-18 2021-07-16 Nikang Therapeutics Inc Derivados de anillo tricíclico condensado como inhibidores de la fosfatasa de homología a src 2.
SG11202102981SA (en) 2018-09-25 2021-04-29 Black Diamond Therapeutics Inc Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
EP3856349A1 (fr) 2018-09-25 2021-08-04 Black Diamond Therapeutics, Inc. Compositions d'inhibiteur de tyrosine kinase, procédés de fabrication et procédés d'utilisation
CN112839715A (zh) 2018-09-29 2021-05-25 诺华股份有限公司 抑制shp2活性化合物的制造方法
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
EP3873214A4 (fr) 2018-10-29 2022-07-13 Forma Therapeutics, Inc. Formes solides de (4-(2-fluoro-4-(1-méthyl-1h-benzo[d]imidazol-5-yl)benzoyl)pipérazin-1-yl)(1-hydroxycyclopropyl)méthanone
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
EP3946332A1 (fr) 2019-04-05 2022-02-09 Université de Bretagne Occidentale Inhibiteurs du récepteur 2 activé par une protéase pour le traitement d'une neuropathie sensorielle induite par une intoxication neurotoxique marine
WO2021007269A1 (fr) 2019-07-09 2021-01-14 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
US20220298120A1 (en) 2019-08-15 2022-09-22 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
CR20220169A (es) 2019-10-14 2022-10-27 Incyte Corp Heterociclos bicíclicos como inhibidores de fgfr
WO2021076728A1 (fr) 2019-10-16 2021-04-22 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
EP4069696A1 (fr) 2019-12-04 2022-10-12 Incyte Corporation Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr
WO2021195206A1 (fr) 2020-03-24 2021-09-30 Black Diamond Therapeutics, Inc. Formes polymorphes et utilisations associées
WO2022043556A1 (fr) 2020-08-31 2022-03-03 Novartis Ag Composition pharmaceutique stable
EP4204021A1 (fr) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Méthode de traitement de cancers exprimant le psma
WO2022043558A1 (fr) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Méthode de traitement de cancers exprimant le psma
WO2022140472A1 (fr) 2020-12-22 2022-06-30 Nikang Therapeutics, Inc. Composés pour la dégradation de la kinase 2 dépendante des cyclines par l'intermédiaire d'une voie de l'ubiquitine-protéosome
WO2022152821A1 (fr) 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Composés d'isoindolinone
WO2022170052A1 (fr) 2021-02-05 2022-08-11 Black Diamond Therapeutics, Inc. Dérivés de quinazoline, dérivés de pyridopyrimidine, dérivés de pyrimidopyrimidine et leurs utilisations
WO2022219407A1 (fr) 2021-04-14 2022-10-20 Monte Rosa Therapeutics Ag Composés d'iso-indolinone
EP4323349A1 (fr) 2021-04-14 2024-02-21 Monte Rosa Therapeutics AG Composés amide d'isoindolinone utilisés pour traiter des maladies associées à gspt1
EP4352059A1 (fr) 2021-06-09 2024-04-17 Incyte Corporation Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr
EP4370522A1 (fr) 2021-07-14 2024-05-22 Nikang Therapeutics, Inc. Dérivés d'alkylidène en tant qu'inhibiteurs de kras
US20230303509A1 (en) 2022-03-28 2023-09-28 Nikang Therapeutics, Inc. Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors
WO2023240024A1 (fr) 2022-06-08 2023-12-14 Nikang Therapeutics, Inc. Dérivés de sulfamide utilisés en tant qu'inhibiteurs de kinase 2 dépendant de la cycline
WO2024102849A1 (fr) 2022-11-11 2024-05-16 Nikang Therapeutics, Inc. Composés bifonctionnels contenant des dérivés de pyrimidine 2,5-substitués pour dégrader la kinase 2 dépendante des cyclines par l'intermédiaire d'une voie ubiquitine-protéasome

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE479651T1 (de) * 1997-11-05 2010-09-15 Novartis Pharma Gmbh Dipeptide nitrile
AU2560300A (en) 1999-02-20 2000-09-04 Astrazeneca Ab Acetamido acetonitrile derivatives as inhibitors of cathepsin l and/or cathepsins
CN1364155A (zh) * 1999-03-15 2002-08-14 Axys药物公司 用作蛋白酶抑制剂的n－氰基甲基酰胺
EP1212302A1 (fr) * 1999-09-16 2002-06-12 Axys Pharmaceuticals, Inc. Composes et compositions pharmaceutiques utilises comme inhibiteurs de la cathepsine s
GB0003111D0 (en) * 2000-02-10 2000-03-29 Novartis Ag Organic compounds
DE60113406T2 (de) * 2000-05-15 2006-06-29 Novartis Ag N-substituierte peptidylnitrile als cystein-cathepsin-inhibitoren
AU2002254099B2 (en) * 2001-03-02 2006-07-06 Axys Pharmaceuticals, Inc. Cathepsin cysteine protease inhibitors
EP1595363B1 (fr) * 2001-08-15 2016-07-13 The Board of Governors for Higher Education State of Rhode Island and Providence Plantations Procede et dispositif de memoire cache du protocole scsi vers le protocole ip
WO2003041649A2 (fr) * 2001-11-13 2003-05-22 Merck Frosst Canada & Co. Derives cyanoalkylamino utilises comme inhibiteurs de la protease
AU2003219953B8 (en) 2002-03-05 2008-09-25 Axys Pharmaceuticals, Inc. Cathepsin cysteine protease inhibitors
KR20060079143A (ko) * 2003-09-18 2006-07-05 액시스 파마슈티컬스 인코포레이티드 시스테인 프로테아제 억제제로서의 할로알킬 함유 화합물
AR055283A1 (es) * 2004-11-23 2007-08-15 Merck Frosst Canada Ltd Inhibidores de cisteinproteasa de catepsina
EP1891003A4 (fr) * 2005-06-02 2010-07-21 Merck Frosst Canada Ltd Derives de fluoroalkylamine utilises comme inhibiteurs de la cathepsine

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060287373A1 (en) * 2003-08-21 2006-12-21 Gauthier Jacques Y Cathepsin cysteine protease inhibitors
WO2005019161A1 (fr) * 2003-08-21 2005-03-03 Merck Frosst Canada Ltd. Inhibiteurs de cathepsine et de cysteine protease
US7312353B2 (en) 2003-08-21 2007-12-25 Merck Frost Canada & Co. Cathespin cysteine protease inhibitors
US7482448B2 (en) 2003-10-24 2009-01-27 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
WO2006017455A3 (fr) * 2004-08-04 2006-04-06 Merck & Co Inc Procédé diastéréosélectif d’amination réductrice
CN1993314B (zh) * 2004-08-04 2011-11-02 默沙东公司 非对映异构选择性还原胺化方法
AU2005271620B2 (en) * 2004-08-04 2011-03-24 Merck Frosst Canada Ltd Diastereoselective reductive amination process
WO2006017455A2 (fr) 2004-08-04 2006-02-16 Merck & Co., Inc. Procédé diastéréosélectif d’amination réductrice
US20060069122A1 (en) * 2004-09-29 2006-03-30 Anormed Inc. Chemokine-binding heterocyclic compound salts, and methods of use thereof
US7723525B2 (en) * 2004-09-29 2010-05-25 Genzyme Corporation Chemokine-binding heterocyclic compound salts, and methods of use thereof
US20060111440A1 (en) * 2004-11-23 2006-05-25 Gauthier Jacques Y Cathepsin cysteine protease inhibitors
WO2006056047A1 (fr) * 2004-11-23 2006-06-01 Merck Frosst Canada Ltd. Inhibiteurs de la cysteine-protease cathepsine
US20070293578A1 (en) * 2004-11-23 2007-12-20 Gauthier Jacques Y Cathepsin Cysteine Protease Inhibitors
US7407959B2 (en) 2004-11-23 2008-08-05 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
NO339125B1 (no) * 2004-11-23 2016-11-14 Merck Canada Inc Forbindelser som er kathepsincysteinproteaseinhibitorer, et farmasøytisk akseptabelt salt, en stereoisomer eller et N-oksidderivat derav, et farmasøytisk preparat eller en kombinasjon derav, samt anvendelse derav for fremstilling av et medikament.
US20090264479A1 (en) * 2005-07-26 2009-10-22 Cameron Black Papain Family Cysteine Protease Inhibitors for the Treatment of Parasitic Diseases
US7781487B2 (en) * 2006-10-04 2010-08-24 Virobay, Inc. Di-fluoro containing compounds as cysteine protease inhibitors
US20080293819A1 (en) * 2006-10-04 2008-11-27 Virobay, Inc. Di-fluoro containing compounds as cysteine protease inhibitors
US20080214676A1 (en) * 2006-10-04 2008-09-04 Virobay, Inc. Di-fluoro containing compounds as cysteine protease inhibitors
US8748649B2 (en) 2006-10-04 2014-06-10 Virobay, Inc. Di-fluoro containing compounds as cysteine protease inhibitors
US7893112B2 (en) 2006-10-04 2011-02-22 Virobay, Inc. Di-fluoro containing compounds as cysteine protease inhibitors
US8367732B2 (en) 2006-10-04 2013-02-05 Virobay, Inc. Di-fluoro containing compounds as cysteine protease inhibitors
US20110172310A1 (en) * 2006-10-04 2011-07-14 Virobay, Inc. Di-fluoro containing compounds as cysteine protease inhibitors
US20100130782A1 (en) * 2007-04-02 2010-05-27 Merck Frosst Canada Ltd. Amidation process for the preparation of cathepsin k inhibitors
US8273913B2 (en) * 2007-04-02 2012-09-25 Merck Canada Inc. Amidation process for the preparation of cathepsin K inhibitors
US8642799B2 (en) 2007-11-29 2014-02-04 Merck Canada Inc. Cysteine protease inhibitors for the treatment of parasitic diseases
US20100305056A1 (en) * 2007-11-29 2010-12-02 Merck Frosst Canada Ltd. Cysteine protease inhibitors for the treatment of parasitic disease
US20090291945A1 (en) * 2008-04-09 2009-11-26 Teijin Pharma Limited Cysteine protease inhibitors
US20110065800A1 (en) * 2008-05-14 2011-03-17 Haihong Fan Formulations for cathepsin k inhibitors
US8975296B2 (en) 2008-05-14 2015-03-10 Merck Sharp & Dohme Corp. Formulations for cathepsin K inhibitors
WO2009140105A3 (fr) * 2008-05-14 2010-01-07 Merck & Co., Inc. Préparations pour inhibiteurs de la cathepsine k
US8324417B2 (en) 2009-08-19 2012-12-04 Virobay, Inc. Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof
US20110046406A1 (en) * 2009-08-19 2011-02-24 Virobay, Inc. Process for the preparation of (s)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof
US10494364B2 (en) 2015-08-29 2019-12-03 Sunshin Lake Pharma Co., Ltd Cathepsin K inhibitors and application thereof
RU2772276C2 (ru) * 2017-01-24 2022-05-18 Астеллас Фарма Инк. Фенилдифторметилзамещенное соединение пролинамида
US11299478B2 (en) 2018-03-28 2022-04-12 Hanlim Pharmaceutical Co., Ltd. 2-cyanopyrimidin-4-yl carbamate or urea derivative or salt thereof, and pharmaceutical composition including same

Also Published As

Publication number Publication date
NO20044207L (no) 2004-11-24
RU2312861C2 (ru) 2007-12-20
US20110230446A1 (en) 2011-09-22
HRP20040800B1 (en) 2012-11-30
PL215865B1 (pl) 2014-02-28
IS2549B (is) 2009-10-15
AU2003219953B8 (en) 2008-09-25
HRP20040800A2 (en) 2005-04-30
ES2305452T3 (es) 2008-11-01
US8318748B2 (en) 2012-11-27
IL163748A0 (en) 2005-12-18
KR100975784B1 (ko) 2010-08-17
AU2003219953B2 (en) 2007-11-01
EP1482924A4 (fr) 2006-03-08
DK1482924T3 (da) 2008-09-29
SI1482924T1 (sl) 2008-12-31
MXPA04008621A (es) 2004-12-06
AU2003219953A1 (en) 2003-09-22
MA27295A1 (fr) 2005-05-02
CA2477657C (fr) 2011-04-26
CY1111130T1 (el) 2015-06-11
RU2004129587A (ru) 2005-05-10
JP4918456B2 (ja) 2012-04-18
CN1638757A (zh) 2005-07-13
BRPI0308208B8 (pt) 2021-05-25
EP1482924A2 (fr) 2004-12-08
US20080188529A1 (en) 2008-08-07
US8772336B2 (en) 2014-07-08
JP2005526753A (ja) 2005-09-08
BR0308208A (pt) 2005-01-11
WO2003075836A2 (fr) 2003-09-18
IS7400A (is) 2004-08-12
ATE395911T1 (de) 2008-06-15
HK1080375A1 (en) 2006-04-28
JP4201716B2 (ja) 2008-12-24
NZ534583A (en) 2006-11-30
US20130035312A1 (en) 2013-02-07
EP1482924B1 (fr) 2008-05-21
PT1482924E (pt) 2008-08-27
US20140256743A1 (en) 2014-09-11
PL372204A1 (en) 2005-07-11
BRPI0308208B1 (pt) 2017-04-18
KR20040095262A (ko) 2004-11-12
DE60321141D1 (en) 2008-07-03
CA2477657A1 (fr) 2003-09-18
NO335099B1 (no) 2014-09-15
US7973037B2 (en) 2011-07-05
JP2008115177A (ja) 2008-05-22
CL2003001743A1 (es) 2005-05-06
IL163748A (en) 2013-10-31
US20050240023A1 (en) 2005-10-27
ECSP045261A (es) 2004-10-26
US7375134B2 (en) 2008-05-20
WO2003075836A3 (fr) 2004-07-15
CN100430052C (zh) 2008-11-05

Similar Documents

Publication Publication Date Title
US8772336B2 (en) Cathepsin cysteine protease inhibitors
EP1372655B1 (fr) Inhibiteurs de cathepsines de la cysteine protease
US7687524B2 (en) Cathepsin cysteine protease inhibitors
US20060287402A1 (en) Cathepsin inhibitors
JP6454335B2 (ja) カテプシンシステインプロテアーゼ阻害剤
US7312353B2 (en) Cathespin cysteine protease inhibitors
US20060166966A1 (en) 4-amino-azepan-3-one compounds as cathepsin k inhibitors useful in the treatment of osteoporosis

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE